

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/26, 9/20, 31/44		A1	(11) International Publication Number: WO 96/01625 (43) International Publication Date: 25 January 1996 (25.01.96)
(21) International Application Number: PCT/SE95/00680 (22) International Filing Date: 7 July 1995 (07.07.95) (30) Priority Data: 9402431-2 8 July 1994 (08.07.94) SE		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(71) Applicant (<i>for all designated States except US</i>): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): BERGSTRAND, Pontus, John, Arvid [SE/SE]; Walleriusgatan 4, S-412 58 Göteborg (SE). LÖVGREN, Kurt, Ingmar [SE/SE]; Violinvägen 2D, S-435 44 Mölnlycke (SE). (74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).		Published <i>With international search report.</i>	

(54) Title: MULTIPLE UNIT TABLETED DOSAGE FORM CONTAINING PROTON PUMP INHIBITOR

(57) Abstract

A new pharmaceutical multiple unit tableted dosage form containing an acid labile, pharmaceutically active substance with gastric inhibitory effect, or one of its single enantiomers or an alkaline salt thereof, a method for the manufacture of such a formulation, and the use of such a formulation in medicine.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Multiple unit tabletted dosage form containing proton pump inhibitor.

Field of the invention

5


- The present invention is related to new pharmaceutical preparations in the form of a multiple unit tableted dosage form comprising acid labile heterocyclic compounds or one of its single enantiomers or alkaline salts thereof with gastric acid inhibitory effect. The novel tableted dosage form is intended for oral use.
- 10 Furthermore, the present invention refers to a method for the manufacture of such preparations and, to the use of such preparations in medicine.

Background of the invention

15

Acid labile heterocyclic compounds with gastric inhibitory effect are for instance compounds described in EP-A1-0005129, WO 90/06925 and WO 91/19712. The following compounds I and II are of specific interest for the novel tableted dosage form according to the present invention


20



I

5-Carbomethoxy-6-methyl-2-[(3,4-dimethoxy-2-pyridinyl)-methyl]sulfinyl-1H-benzimidazole and

25



5-Fluoro-2-[[[(4-cyclopropylmethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole.

5

Compounds I and II used in the compositions of the invention may be used in neutral form or in the form of an alkaline salt, such as for instance the Mg^{2+} , Ca^{2+} , Na^{2+} or K^+ salts, preferably Mg^{2+} salts. These compounds may be used in racemic form or in the form of one of its single enantiomers. The latter are described in

10 PCT/SE 94/00510 and PCT/SE 94/00511 both filed on May 27, 1994.

These active substances are, as already mentioned, useful for inhibiting gastric acid secretion in mammals and man. In a more general sense, they may be used for prevention and treatment of gastric acid related diseases in mammals and
 15 man, including e.g. reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, they may be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro-esophageal reflux disease, and in patients with
 20 gastrinomas. They may also be used in patients in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre-and postoperatively to prevent acid aspiration of gastric acid and to prevent and treat stress ulceration. Further, they may be useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections and diseases related to these.

25

These compounds with gastric inhibitory effect are, however, susceptible to degradation/transformation in acidic and neutral media. The degradation is catalyzed by acidic compounds and they are usually stabilized in mixtures with alkaline compounds. The stability of the compounds is also affected by moisture,

5 heat, organic solvents and to some degree by light.

In respect to the stability properties of these acidic susceptible compounds, it is obvious that the active compound in an oral solid dosage form must be protected from contact with the acidic gastric juice and must be transferred in intact form to

10 that part of the gastrointestinal tract where pH is near neutral and where rapid absorption of the pharmaceutically active substance can occur.

A pharmaceutical oral dosage form of the specific active compound is best protected from contact with acidic gastric juice by an enteric coating layer. In US-

15 A 4,853,230 enteric coated preparations of acid labile substances are described. Said preparations contain an alkaline core comprising the active substance, a separating layer and an enteric coating layer. In order to further enhance the stability during storage the prepared formulation may optionally be packed with a desiccant.

20 There has been a demand for development of new enteric coating layered multiple unit preparations with good chemical and mechanical stability making it possible to produce well functioning and patient-friendly packages, such as for instance blister package. Furthermore, there is a demand for formulations having

25 an improved patient acceptance, such as divisible and/or dispersible tablets.

A good mechanical stability can be obtained with an enteric coating layered tablet (WO 95/01783 describes such a tablet comprising the acid labile compound, omeprazole). However, only an enteric coating layered multiple unit tablet can be

30 made divisible and dispersible. A further advantage of a multiple unit dosage

form is that it disperses into a multitude of small units in the stomach upon administration.

- Prior art discloses many different types of multiple unit dosage forms. Usually
- 5 this type of formulation is requested for controlled release formulations, such as sustained release formulations. Typically, the multiple unit formulation may be a tablet which disintegrates in the stomach to make available a multitude of coated units, or pellets filled in a capsule. (See for example EP 0 080 341 and US-A 4,853,230).
- 10 An example to obtain a controlled release dosage form releasing the active substance by diffusion through a membrane is described in US-A 4,927,640, i.e. a multiple-unit system containing small inert cores coated with active substance and a release controlling polymeric membrane. The mechanical properties of such
- 15 multiple units formulated into tablets are reported in Pharmaceutical Research, 10 (1993), p. S-274. Other examples of controlled release dosage forms are for example described in Aulton M.E. (Churchill Livingstone), Pharmaceutics: The science of dosage form design (1988), p. 316-321.
- 20 Even if there are examples in the prior art mentioning that pellets may be formulated into tablets, there are no examples describing any compositions of such a tablet formulation or a technique to manufacture such a formulation comprising an acid labile substance. In practice, problems arise when enteric coating layered pellets, especially containing acidic susceptible substances are
- 25 compressed into tablets. If the enteric coating layer does not withstand the compression of the pellets into a tablet the susceptible active substance will be destroyed by penetrating acidic gastric juice, i.e. the acid resistance of the enteric coating layer of the pellets will not be sufficient in the tablet after compression. The above described problems are well illustrated in Reference Examples below.

Further, controlled release tablets from enteric coated particles are described in Drugs Made In Germany, 37 No. 2 (1994), p. 53. The teaching in this reference is that a combination of a methacrylic acid copolymer (L30D-55) and a copolymer of ethyl acrylate and methyl methacrylate (NE30D) is suitable as coating polymers

5 for enteric coated particles compressed into tablets. Reference Example III shows that this recommendation is not applicable when formulating multiple unit tableted dosage forms of acidic susceptible substances. The acid resistance of the pellets compressed into a tablet is too low. The cited reference Drugs Made In Germany also states that the use of the copolymer L30D-55 without the addition of

10 the copolymer NE30D as material for enteric coating layers will result in coated pellets which cannot withstand compression forces used during the tableting process. With reference to this statement it is surprisingly found that pellets covered with L30D-55 according to this invention, see Examples below, are possible to compress into tablets with fulfilled requirements including acceptable

15 acid resistance of the tablet.

The Applicant is not aware of any working example in the prior art of a multiple unit tableted dosage form comprising an acid labile heterocyclic compound.

20

Description of the invention

The Applicant has now surprisingly found that tablets according to the present invention comprising enteric coating layered units containing an acid labile heterocyclic compound in the form of compound I or II, or one of its single enantiomers or an alkaline salt thereof can be manufactured by compressing said units into tablets without significantly affecting the properties of the enteric coating layer. As explained above, if the enteric coating layer is damaged during compression of the enteric coating layered units the acid resistance of said enteric

25 coating layer in the manufactured tablet will not be sufficient and the manufactured tablets will not fulfill standard requirements on enteric coated

30

articles, such as e.g. those defined in the United States Pharmacopeia, hereby incorporated in a whole by reference. In the following the expression "compounds I and II, respectively" is including the single enantiomers of said compounds as well as an alkaline salt of said compound or of one of its single enantiomers.

5

One object of the present invention is to provide a pharmaceutical multiple unit tableted dosage form comprising compound I or II or one of its single enantiomers or an alkaline salt thereof, in which the active substance is in the form of individually enteric coating layered units compressed into a tablet. The enteric 10 coating layer(s) covering the individual units of active substance has properties such that the compression of the units into a tablet does not significantly affect the acid resistance of the individually enteric coating layered units. The active substance is prevented from degradation and dissolution in acidic media and has a good stability during long-term storage. The enteric coating layer covering the 15 individual units disintegrates/dissolves rapidly in near neutral or alkaline media.

Another object of the present invention is to provide a pharmaceutical multiple unit tableted dosage form comprising compound I or II or one of its single enantiomers or an alkaline salt thereof which is suitable for press-through blister 20 packages and which also has improved patient acceptance.

A further object of the present invention is to provide a multiple unit tableted dosage form comprising compound I or II or one of its single enantiomers or an alkaline salt thereof which is divisible and easy to handle. The multiple unit 25 tableted dosage form may be dispersed in an aqueous liquid and can be given to patients with swallowing disorders and in pediatrics. Such a suspension of dispersed enteric coating layered units of appropriate size can be used for oral administration and also for feeding through a naso-gastric tube.

Detailed description of the invention.

The novel multiple unit tableted dosage form comprising compound I or II or one of its single enantiomers or an alkaline salt thereof is characterized in the
5 following way. Individually enteric coating layered units containing the active substance, and optionally alkaline substances, are mixed with tablet excipients and compressed into multiple unit tableted dosage forms. With the expression "individual units" is meant small beads, particles, granules or pellets, in the following referred to as pellets.

10

The compaction process (compression) for formulating the multiple unit tableted dosage form must not significantly affect the acid resistance of the enteric coating layered pellets. In other words the mechanical properties, such as the flexibility and hardness as well as the thickness, of the enteric coating layer(s)
15 must secure that the requirements on enteric coated articles in the United States Pharmacopeia are accomplished and that the acid resistance does not decrease more than 10 % during the compression of pellets into tablets.

20 The flexibility/hardness of enteric coating layers can be characterized for instance as Vickers hardness measured with a Shimadzu micro hardness indentation tester type HMV 2 000.

25 The acid resistance is defined as the amount of active substance in tablets or pellets after being exposed to simulated gastric fluid, USP, or to 0.1 M HCl(aq) relative to that of unexposed tablets or pellets, respectively. The test is accomplished in the following way. Tablets or pellets are exposed to simulated gastric fluid at a temperature of 37°C. The tablets disintegrate and release the enteric coating layered pellets to the medium. After two hours the pellets are removed and analyzed for content of active substance using High Performance
30 Liquid Chromatography (HPLC). Presented values of acid resistance are averages of at least three individual determinations.

Core material

- The core material for the individually enteric coating layered pellets can be
- 5 constituted according to different principles. Seeds layered with active substance in the form of compounds I and II, respectively, or one of its single enantiomers or an alkaline salt thereof, optionally mixed with alkaline compounds, can be used as the core material for the further processing.
- 10 The seeds, which are to be layered with the active substance, can be water insoluble seeds comprising different oxides, celluloses, organic polymers and other materials, alone or in mixtures or water soluble seeds comprising different inorganic salts, sugars, non-pareils and other materials, alone or in mixtures. Further, the seeds may comprise active substance in the form of crystals,
- 15 agglomerates, compacts etc. The size of the seeds is not essential for the present invention and may vary between approximately 0.1 and 2 mm. The seeds layered with active substance are produced either by powder or solution/suspension layering using for instance granulating or spray coating/layering equipment.
- 20 Before the seeds are layered, the active substance may be mixed with further components. Such components can be binders, surfactants, fillers, disintegrating agents, alkaline additives or other pharmaceutically acceptable ingredients, alone or in mixtures. The binders are for example celluloses such as hydroxypropyl methylcellulose, hydroxypropyl cellulose and carboxymethylcellulose sodium,
- 25 polyvinyl pyrrolidone, sugars, starches and other pharmaceutically acceptable substances with cohesive properties. Suitable surfactants are found in the groups of pharmaceutically acceptable non-ionic or ionic surfactants such as for instance sodium lauryl sulfate.
- 30 Alternatively, the compounds I and II, respectively, optionally mixed with alkaline compounds and further mixed with suitable constituents can be

- formulated into core material. Said core materials may be produced by extrusion/spheronization, balling or compression utilizing different process equipments. The size of the formulated core materials is approximately between 0.1 and 4 mm and preferably between 0.1 and 2 mm. The manufactured core
- 5 materials can further be layered with additional ingredients comprising active substance and/or be used for further processing.
- The active substance is mixed with pharmaceutical constituents to obtain preferred handling and processing properties and a suitable concentration of the
- 10 active substance in the final mixture. Pharmaceutical constituents such as fillers, binders, lubricants, disintegrating agents, surfactants and other pharmaceutically acceptable additives, can be used.
- The active substance may also be mixed with an alkaline pharmaceutically acceptable substance (or substances). Such substances can be chosen among, but are not restricted to, substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; aluminium hydroxide/sodium bicarbonate coprecipitate; substances normally used in antacid preparations such
- 15 as aluminium, calcium and magnesium hydroxides; magnesium oxide or composite substances, such as $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$, $(\text{Mg}_6\text{Al}_2(\text{OH})_{16}\text{CO}_3 \cdot 4\text{H}_2\text{O})$, $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$ or similar compounds; organic pH-buffering substances such as trihydroxymethylaminomethane, basic amino acids and their salts or other similar, pharmaceutically acceptable pH-buffering substances.
- 20
- 25 Alternatively, the aforementioned core material can be prepared by using spray drying or spray congealing technique.
- The active substance is in the form of 5-fluoro-2[[4-cyclopropylmethoxy-2-
- 30 pyridinyl)methyl]-sulfinyl]-1H-benzimidazole, 5-carbomethoxy-6-methyl-2-[(3,4-

dimethoxy-2-pyridinyl)methyl]sulfinyl-1H-benzimidazole, respectively, or one of its single enantiomers or an alkaline salt thereof. These compounds have an asymmetric centre in the sulfur atom, i.e. exists as two optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50 % of each 5 enantiomer) and unequal mixtures of the two enantiomers are suitable for the pharmaceutical formulation according to the present invention.

Enteric coating layer(s)

10

Before applying enteric coating layer(s) onto the core material in the form of individual pellets, said pellets may optionally be covered with one or more separating layers comprising pharmaceutical excipients optionally including alkaline compounds such as for instance pH-buffering compounds. This/these 15 separating layer(s) separate(s) the core material from the outer layer(s) being enteric coating layer(s).

The separating layer(s) can be applied to the core material by coating or layering procedures in suitable equipments such as coating pan, coating granulator or in a 20 fluidized bed apparatus using water and/or organic solvents for the coating process. As an alternative the separating layer(s) can be applied to the core material by using powder coating technique. The materials for separating layers are pharmaceutically acceptable compounds such as, for instance, sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, 25 hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose sodium and others, used alone or in mixtures. Additives such as plasticizers, colorants, pigments, fillers, anti-tacking and anti-static agents, such as for instance magnesium stearate, titanium dioxide, talc and other additives may also be included into the separating layer(s).

30

- When the optional separating layer(s) is applied to the core material it may constitute a variable thickness. The maximum thickness of the optional separating layer(s) is normally only limited by processing conditions. The separating layer(s) may serve as a diffusion barrier and may act as a pH-buffering zone. The pH-
- 5 buffering properties of the separating layer(s) can be further strengthened by introducing into the layer(s) substances chosen from a group of compounds usually used in antacid formulations such as, for instance, magnesium oxide, hydroxide or carbonate, aluminium or calcium hydroxide, carbonate or silicate; composite aluminium/magnesium compounds such as, for instance
- 10 $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$, $(\text{Mg}_6\text{Al}_2(\text{OH})_{16}\text{CO}_3 \cdot 4\text{H}_2\text{O})$, $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$ aluminium hydroxide/sodium bicarbonate coprecipitate or similar compounds; or other pharmaceutically acceptable pH-buffering compounds such as, for instance the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric, carbonic, citric or other suitable, weak, inorganic or organic acids; or
- 15 suitable organic bases, including basic amino acids and salts thereof. Talc or other compounds may be added to increase the thickness of the layer(s) and thereby strengthen the diffusion barrier. The optionally applied separating layer(s) is not essential for the invention. However the separating layer(s) may improve the chemical stability of the active substance and/or the physical properties of the
- 20 novel multiple unit tableted dosage form.

- One or more enteric coating layers are applied onto the core material or onto the core material covered with separating layer(s) by using a suitable coating technique. The enteric coating layer material may be dispersed or dissolved in
- 25 either water or in suitable organic solvents. As enteric coating layer polymers one or more separately or in combination of the following can be used; e.g. solutions or dispersions of methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate,
- 30 carboxymethylcellulose, shellac or other suitable enteric coating layer polymer(s).

The enteric coating layers contain pharmaceutically acceptable plasticizers to obtain the desired mechanical properties, such as flexibility and hardness of the enteric coating layers. Such plasticizers are for instance, but not restricted to,

- 5 triacetin, citric acid esters, phthalic acid esters, dibutyl sebacate, cetyl alcohol, polyethylene glycols, polysorbates or other plasticizers.

The amount of plasticizer is optimized for each enteric coating layer formula, in relation to selected enteric coating layer polymer(s), selected plasticizer(s) and the

- 10 applied amount of said polymer(s), in such a way that the mechanical properties, i.e. flexibility and hardness of the enteric coating layer(s) for instance exemplified as Vickers hardness, are adjusted so that the acid resistance of the pellets covered with enteric coating layer(s) does not decrease significantly during the compression of pellets into tablets. The amount of plasticizer is usually above 10
15 % by weight of the enteric coating layer polymer(s), preferably 15 - 50 % and more preferably 20 - 50 %. Additives such as dispersants, colorants, pigments, polymers e.g. poly(ethylacrylat, methylmethacrylat), anti-tacking and anti-foaming agents may also be included into the enteric coating layer(s). Other compounds may be added to increase film thickness and to decrease diffusion of
20 acidic gastric juices into the acidic susceptible material.

To protect an acidic susceptible substance and to obtain an acceptable acid resistance of the multiple unit tableted dosage form according to the invention, the enteric coating layer(s) constitutes a thickness of approximately at least 10 µm,

- 25 preferably more than 20 µm. The maximum thickness of the applied enteric coating layer(s) is normally only limited by processing conditions.

Over-coating layer

Pellets covered with enteric coating layer(s) may further be covered with one or
5 more over-coating layer(s). The over-coating layer(s) can be applied to the enteric
coating layered pellets by coating or layering procedures in suitable equipments
such as coating pan, coating granulator or in a fluidized bed apparatus using
water and/or organic solvents for the coating or layering process. The materials
for over-coating layers are pharmaceutically acceptable compounds such as, for
10 instance, sugar, polyethylene glycol, polyvinyl-pyrrolidone, polyvinyl alcohol,
polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose,
hydroxypropyl methyl cellulose, carboxymethyl-cellulose sodium and others,
used alone or in mixtures. Additives such as plasticizers, colorants, pigments,
fillers, anti-tacking and anti-static agents, such as for instance magnesium stearate,
15 titanium dioxide, talc and other additives may also be included into the over-
coating layer(s). Said over-coating layer may further prevent potential
agglomeration of coated pellets, further protect the enteric coating towards
cracking during the compaction process and enhance the tabletting process. The
maximum thickness of the applied over-coating layer(s) is normally only limited
20 by processing conditions.

Tablets

25 The enteric coating layered pellets are mixed with tablet excipients and
compressed into a multiple unit tableted dosage form according to the present
invention. The enteric coating layered pellets with or without an over-coating
layer are mixed with tablet excipients such as fillers, binders, disintegrants,
lubricants and other pharmaceutically acceptable additives and compressed into
30 tablets. The compressed tablet is optionally coated with filmforming agent(s) to
obtain a smooth surface of the tablet and further enhance the stability

of the tablet during packaging and transport. Such a tablet coating layer may further comprise additives like anti-tacking agents, colorants and pigments or other additives to obtain a tablet of good appearance.

- 5 The amount of enteric coating layered pellets constitutes less than 75% by weight of the total tablet weight and preferably less than 60 %. By choosing small enteric coating layered pellets in the formulation according to the present invention, the number of pellets in each tablet can be held high which in turn makes the tablet divisible with retained dosing accuracy.

10

- The mechanical properties, i.e. the flexibility and hardness of the enteric coating layer are essential for the acid resistance of the multiple unit tableted dosage form. The flexibility/hardness of the enteric coating layer surface may be characterized as a preliminary process parameter in the form of Vickers hardness, measured on 15 enteric coating layered pellet(s) before compression of said pellets into tablets. The Vickers hardness may be measured with a Shimadzu micro hardness indentation tester type HMV 2000 (Micro Hardness Testing Machines for Vickers and Knoop Hardness JIS B 7734-1984 and JIS Z 2251-1980). The ability of the enteric coating layer(s) to withstand compression into tablets is, of course, a function of both the 20 amount of applied coating layer and the mechanical properties of said coating layer material. To obtain well functioning enteric coating layered pellets with a reasonable amount of enteric coating layer material and which pellets can be compressed into tablets without significantly affecting the acid resistance, an enteric coating layer surface with a Vickers hardness of less than 8 is preferred. In 25 case the pellets are covered with an over-coating layer the Vickers hardness of the enteric coating layer must be characterized before the over-coating layer is applied. A harder over-coating layer (Vickers hardness higher than 8) can be applied on top of a flexible and softer (Vickers hardness less than 8) enteric coating layer with retained acid resistance during compaction.

30

Thus, the formulation according to the invention consists of core material containing active substance in the form of compounds I and II, respectively mixed with alkaline compound(s), and excipients. The addition of an alkaline material may not be necessary, but such a substance may further enhance the stability of

5 the active substance. The core material is optionally covered with one or more separating layer(s) optionally containing alkaline substance(s). The pellets, optionally covered with a separating layer(s), are then covered with one or more enteric coating layer(s) making the pellets insoluble in acidic media, but disintegrating/dissolving in near neutral to alkaline media such as, for instance

10 the liquids present in the proximal part of the small intestine, the site where dissolution is wanted. The enteric coating layered pellets may further be covered with an over-coating layer before being formulated into the multiple unit tableted dosage form.

15

Process

The process for the manufacture of the dosage form represents a further aspect of the invention. The pharmaceutical processes can preferably be completely water-based and there are different descriptions given in the accompanying examples below.

25

The preparation according to the invention is also especially advantageous in reducing gastric acid secretion. Such a multiple unit tableted dosage form is administered one to several times a day. The typical daily dose of the active substance varies and will depend on various factors such as the individual requirements of the patients, the mode of administration and disease. In general the daily dose will be in the range of 1-1000 mg of active substance.

The preparation according to the present invention is also suitable for dispersion in an aqueous liquid with neutral or slightly acidic pH-value before being orally administered or fed through a naso-gastric tube.

5

The invention is illustrated more in detail by the following examples.

EXAMPLES

10 Example 1

Core material

5-Fluoro-2[((4-cyclopropylmethoxy-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole sodium

312 g

Sugar sphere seeds

300 g

15 Hydroxypropyl methylcellulose

80 g

Purified water

1 520 g

Separating layer

Core material

300 g

20 Hydroxypropyl cellulose

21 g

Talc

37 g

Magnesium stearate

2 g

Purified water

400 g

25 Enteric coating layer

Pellets covered with separating layer

300 g

Methacrylic acid copolymer

285 g

Triethyl citrate

85.5 g

Mono- and diglycerides

14 g

30 Polysorbate 80

1 g

Purified water

557 g

Tablets

Enteric coating layered pellets

150 g

Microcrystalline cellulose

349 g

Sodium stearyl fumarate 1 g

Solution layering is performed in a fluid bed apparatus using bottom spray technique. 5-Fluoro-2[[[(4-cyclopropylmethoxy-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole sodium is sprayed onto sugar sphere seeds from a water solution containing the dissolved binder. The size of sugar sphere seeds are in the range of 5 0.25 to 0.35 mm.

The prepared core material is covered with separating layer in a fluid bed apparatus with a hydroxypropyl cellulose solution containing talc and magnesium stearate. The enteric coating layer is sprayed as a water dispersion 10 onto the pellets covered with separating layer in a fluid bed apparatus. The Vickers hardness on enteric coating layered pellets is measured to a value of 2.

Enteric coating layered pellets and tablet excipients are mixed and compressed into tablets using a single punch tabletting machine using 12 mm round punches. 15 Hardness of tablet measured on a Schleuniger hardness tester is determined to 95 - 116 N.

Example 2

20 Core material

5-Carbomethoxy-6-methyl-2-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl-1H-benzimidazole magnesium	600 g
Mannitol	1000 g
Microcrystalline cellulose	300 g
25 Hydroxypropyl cellulose	100 g
Sodium lauryl sulfate	6 g
Purified water	802 g

Separating layer

Core material	400 g
Hydroxypropyl methylcellulose	48 g
Purified water	960 g

Enteric coating layer

Pellets covered with separating layer	200 g
Methacrylic acid copolymer	100 g
Triethyl citrate	30 g
5 Mono- and diglycerides	5 g
Polysorbate 80	0.5 g
Purified water	309 g

Tablets

10 Enteric coating layered pellets	200 g
Microcrystalline cellulose	299 g
Sodium stearyl fumarate	1.2 g

- 15 Sodium lauryl sulfate is dissolved in purified water to form the granulation liquid. 5- Carbomethoxy-6-methyl-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl-1H-benzimidazole magnesium, mannitol, microcrystalline cellulose and hydroxypropyl cellulose are dry-mixed. The granulation liquid is added to the powder mixture and the mass is wet-mixed.
- 20 The wet mass is forced through an extruder equipped with screens, aperture size 0.5 mm. The extrudate is spheronized on a friction plate in a spheronizing apparatus. The core material is dried in a fluid bed dryer and classified. The prepared core material is covered with separating layer in a fluid bed apparatus with a hydroxypropyl methyl-cellulose/water solution.
- 25 The enteric coating layer is applied to the pellets covered with separating layer from an aqueous dispersion of methacrylic acid copolymer plasticized with triethyl citrate to which a mono- and diglycerides/polysorbate dispersion has been added. The pellets are dried in a fluid bed apparatus.
- 30 Enteric coating layered pellets, microcrystalline cellulose and sodium stearyl fumarate are mixed and compressed into tablets with a tablet weight corresponding to 20 mg active substance, using a single punch tabletting machine equipped with 10 mm round punches.

Example 3Core material

(-)-5-Carbomethoxy-6-methyl-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl- 5	
1H-benzimidazole magnesium	600 g
Sugar sphere seeds	600 g
Hydroxypropyl methylcellulose	150 g
Colloidal silicon dioxide	4 g
Purified water	1 800 g

10

Separating layer

Core material	500 g
Hydroxypropyl cellulose	40 g
Talc	67 g
Magnesium stearate	6 g
Purified water	800 g

15

Enteric coating layer

Pellets covered with separating layer	500 g
Methacrylic acid copolymer	200 g
Triethyl citrate	60 g
Purified water	392 g

20

Tablets

Enteric coating layered pellets	430 g
Microcrystalline cellulose	871 g
Sodium stearyl fumarate	3 g

- (-)-5-Carbomethoxy-6-methyl-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl-1H-benzimidazole magnesium, part of the hydroxypropyl methylcellulose and colloidal silicon dioxide are dry-mixed forming a powder mixture. Sugar sphere seeds (0.25-0.35 mm) are layered with the powder in a centrifugal fluidized coating granulator while spraying a hydroxypropyl methylcellulose solution (6 %, w/w).
- The prepared core material is dried and covered with separating layer in a centrifugal fluidized coating granulator. A fluid bed apparatus is used for enteric coating layering.

Enteric coating layered pellets and tablet excipients are mixed and compressed into tablets using a rotary tableting machine equipped with 6 pairs of 10 mm round punches. The amount of active substance in the tablet is approx. 20 mg.

5

Example 4

10 Core material

(-)-5-Carbomethoxy-6-methyl-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl- 1H-benzimidazole	400 g
Silicon dioxide seeds	400 g
Hydroxypropyl methylcellulose	100 g
15 Sodium lauryl sulfate	2 g
Purified water	2 000 g

Separating layer

Core material	800 g
20 Hydroxypropyl methylcellulose	65 g
Purified water	1 300 g

Enteric coating layer

Pellets covered with separating layer	500 g
25 Methacrylic acid copolymer	300 g
Polyethylene glycol 400	60 g
Mono- and diglycerides	9 g
Polysorbate 80	1 g
Purified water	800 g

30

Tablets

Enteric coating layered pellets	200 g
Microcrystalline cellulose	598 g
Sodium stearyl fumarate	2 g

35

Suspension layering is performed in a fluid bed apparatus. (-)-5-Carbomethoxy-6-methyl-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl-1H-benzimidazole is sprayed onto the

seeds of silicon dioxide (size range 0.15 - 0.3 mm) from a water suspension containing the dissolved binder and a surface active ingredient.

- 5 The prepared core material is covered with separating layer in a fluid bed apparatus using a hydroxypropyl methylcellulose solution. The enteric coating layer material is sprayed as a water dispersion onto pellets in a fluid bed apparatus. Enteric coating layered pellets and the tabletting excipients are mixed and compressed into tablets as described in Example 1.

10 Example 5

Enteric coating layer

Pellets covered with separating layer (manufacturing and composition as in Example 1)

15	Methacrylic acid copolymer	500 g
	Polyethylene glycol 6000	250 g
	Mono- and diglycerides	75 g
	Polysorbate 80	12.5 g
	Purified water	1.2 g
		490 g

20

Tablets

Enteric coating layered pellets	600 g
Microcrystalline cellulose	1 395 g
Sodium stearyl fumarate	5 g

25

Enteric coated pellets, microcrystalline cellulose and sodium stearyl fumarate are mixed and compressed into tablets as described in Example 3.

Example 6

30

Enteric coating layer

Pellets covered with separating layer (manufacturing and composition as in Example 1)

35	Hydroxypropyl methylcellulose phthalate	400 g
	Diethyl phthalate	400 g
	Ethanol	80 g
	Acetone	1 600 g
		4 000 g

Tablets

Enteric coating layered pellets	500 g
Microcrystalline cellulose	1 500 g
5 Magnesium stearate	5 g

Enteric coating layering is performed by spraying a solution in a fluid bed. Enteric coating layered pellets, microcrystalline cellulose and magnesium stearate are mixed and compressed into tablets as described in Example 3.

10

Example 7Core material

(+)-5-Fluoro-2-[(4-cyclopropylmethoxy-2-pyridinyl)methyl]sulfinyl-1H-	
benzimidazole	400 g
Sugar sphere seeds (non-pareils)	400 g
Hydroxypropyl methylcellulose	80 g
Purified water	1 600 g

20 Separating layer

Core material	800 g
Hydroxypropyl cellulose	40 g
Talc	40 g
Magnesium stearate	8 g
25 Purified water	800 g

Enteric coating layer

Pellets covered with separating layer	800 g
Methacrylic acid copolymer	400 g
30 Triethyl citrate	120 g
Mono- and diglycerides	8 g
Polysorbate 80	1 g
Purified water	800 g

35 Tablets

Enteric coating layered pellets	1 000 g
Dibasic calcium phosphate anhydrous	1 760 g

Microcrystalline cellulose	440 g
Magnesium stearate	16 g

- Suspension layering is performed in a fluid bed apparatus. (+)-5-Fluoro-2-[(4-cyclopropylmethoxy-2-pyridinyl)methyl]sulfinyl-1H-benzimidazole is sprayed onto sugar sphere seeds from a water suspension containing the dissolved binder.
- The prepared core material is covered with separating layer in a fluid bed with a hydroxypropyl cellulose solution containing talc and magnesium stearate. The enteric coating layer is sprayed as a dispersion onto the pellets covered with separating layer in a fluid bed. Enteric coating layered pellets, dibasic calcium phosphate anhydrous in granulated form, microcrystalline cellulose and magnesium stearate are mixed and compressed into tablets as described in Example 3.

Example 8

15

Tablets

Enteric coating layered pellets (manufacturing and composition as in Example 2)

1.00 kg

Microcrystalline cellulose

1.45 kg

20 Anhydrous lactose

0.14 kg

Starch

0.23 kg

Povidone

0.18 kg

Purified water

0.836 kg

- 25 Povidone is dissolved in water. Microcrystalline cellulose, anhydrous lactose and starch are dry-mixed. The povidone solution is added while wet-mixing. The wet mass is dried in an oven. The granulated mass is milled using an oscillating granulator.

- 30 Enteric coating layered pellets and the prepared granulate are mixed and compressed into engraved and scored tablets using a rotary tabletting machine equipped with 16 pairs of oval, 8.5x17 mm, tablet punches.

Example 9Over-coating layer

Enteric coating layered pellets (manufacturing and composition
 5 as in Example 7)

Hydroxypropyl methylcellulose	400 g
Purified water	120 g
	2 280 g

Tablets

10 Over-coating layered pellets	100 g
Microcrystalline cellulose	233 g

In a fluid bed apparatus a hydroxypropyl methylcellulose solution is sprayed onto enteric coating layered pellets. The Vickers hardness on the enteric coating layered pellets before 15 applying the over-coating layer is 2 and the Vickers hardness measured on the over-coating layered pellets is 11. Pellets covered with over-coating layer and microcrystalline cellulose are mixed and compressed into tablets as described in Example 2.

Example 10

20

Core material

5-Fluoro-2{[(4-cyclopropylmethoxy-2-pyridinyl)methyl]-sulfinyl}-1H-benzimidazole magnesium

Sugar sphere seeds	150 g
25 Hydroxypropyl methylcellulose	200 g
Purified water	75 g
	1 500 g

Separating layer

Core material	380 g
30 Hydroxypropyl cellulose	38 g
Talc	65 g
Magnesium stearate	5 g
Purified water	760 g
35 Enteric coating layer	
Pellets covered with separating layer	150 g
Methacrylic acid copolymer	60 g

Triethyl citrate	18 g
Mono- and diglycerides	3 g
Polysorbate 80	0.3 g
Purified water	117 g

5

Tablets

Enteric coating layered pellets	90 g
Microcrystalline cellulose	209 g
Sodium stearyl fumarate	1 g

10 Suspension layering is performed in a fluid bed apparatus. 5-Fluoro-2{[(4-cyclopropylmethoxy-2-pyridinyl)methyl]-sulfinyl}-1H-benzimidazole magnesium is sprayed onto sugar sphere seeds from a water suspension containing the dissolved binder.

15 The prepared core material is covered with separating layer in a fluid bed apparatus. The enteric coating layer is sprayed as a water dispersion onto the pellets covered with separating layer in a fluid bed apparatus.

20 Enteric coating layered pellets and tablet excipients are mixed and compressed into tablets using a single punch tabletting machine using 8 mm round punches. Tablet hardness measured on a Schleuniger hardness tester is determined to 95 - 109 N.

25

Example 11Enteric coating layer

Core material (no separating layer)	500 g
Methacrylic acid copolymer	500 g
Triethyl citrate	150 g
Mono- and diglycerides	25 g
Polysorbate 80	2.5 g
Purified water	978 g

30

Tablets

	Enteric coating layered pellets	800 g
	Microcrystalline cellulose	1 860 g
5	Sodium stearyl fumarate	7 g

Core material is produced as in Example 7.

Enteric coating layered pellets and tablet excipients are compressed as described in Example 3.

10

Example 12

15

Enteric coating layer

	Pellets covered with separating layer	200 g
	Hydroxypropyl methylcellulose acetate succinate	150 g
	Triethyl citrate	55 g
20	Ethanol	1 200 g
	Purified water	300 g

Tablets

	Enteric coating layered pellets	300 g
	Microcrystalline cellulose	700 g

- The pellets covered with separating layer are produced according to Example 10.
 25 The enteric coating layer is sprayed as a solution onto the pellets.
 Enteric coating layered pellets and microcrystalline cellulose are mixed and compressed into tablets as described in Example 1.

Example 13

30

Core material

(+)-5-Fluoro-2[[[4-cyclopropylmethoxy-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole magnesium	200 g
------------------------------------------------------------------------------------------------	-------

Sugar sphere seeds	200 g
Hydroxypropyl cellulose	75 g
Purified water	1 500 g

5 Separating layer

Core material	380 g
Hydroxypropyl cellulose	38 g
Talc	65 g
Magnesium stearate	5 g
10 Purified water	760 g

Enteric coating layer

15 Pellets covered with separating layer	200 g
Methacrylic acid copolymer	150 g
Triethyl citrate	45 g
Mono- and diglycerides	4 g
Polysorbate 80	0.4 g
20 Purified water	300 g

Tablets

Enteric coating layered pellets	100 g
Microcrystalline cellulose	250 g
Sodium stearyl fumarate	1 g

25 Suspension layering is performed in a fluid bed apparatus. (+)-5-Fluoro-2{[(4-cyclopropylmethoxy-2-pyridinyl)methyl]-sulfinyl}-1H-benzimidazole magnesium is sprayed onto sugar sphere seeds from a water suspension containing the dissolved binder.

The prepared core material is covered with separating layer in a fluid bed apparatus. The enteric coating layer is sprayed as a water dispersion onto the 30 pellets covered with separating layer in a fluid bed apparatus.

Enteric coating layered pellets and tablet excipients are mixed and compressed into tablets using 10 mm round punches.

Example 14Enteric coating layer

5	Pellets covered with separating layer	200 g
	Methacrylic acid copolymer	200 g
	Triethyl citrate	60 g
	Mono- and diglycerides	10 g
	Polysorbate 80	1 g
10	Purified water	391 g

Over-coating layer

15	Enteric coating layered pellets	471 g
	Hydroxypropyl methylcellulose	6 g
	Magnesium stearate	0.2 g
	Purified water	120 g

Tablets

20	Over-coating layered pellets	140 g
	Microcrystalline cellulose	114 g
	Sodium stearyl fumarate	0.4 g

- 25 Pellets covered with separating layer are produced according to Example 13.
- The enteric coating layer and the over-coating layer are sprayed onto pellets in a fluid bed apparatus. Over-coating layered pellets and tablet excipients are compressed using a single punch (round, 12 mm) tabletting machine.

Example 15

30

Enteric coating layer

35	Pellets covered with separating layer	200 g
	Methacrylic acid copolymer	40 g
	Triethyl citrate	12 g
	Mono- and diglycerides	2 g
	Polysorbate 80	0.2 g
	Purified water	78 g

Over-coating layer

Enteric coating layered pellets	200 g
Hydroxypropyl methylcellulose	4 g
5 Magnesium stearate	0.1 g

Tablets

Over-coating layered pellets	69 g
Microcrystalline cellulose	230 g
10 Sodium stearyl fumarate	0.7 g

Pellets covered with separating layer are produced according to Example 13.

The enteric coating layer and the over-coating layer are sprayed onto pellets in a
 15 fluid bed apparatus. The amount of enteric coating layer material used in this example corresponds to an enteric coating layer thickness of approx. 20 µm. Over-coating layered pellets and tablet excipients are compressed using a single punch (round, 10 mm) tabletting machine.

20 Example 16Enteric coating layer

Pellets covered with separating layer	500 g
Cellulose acetate phtalate	375 g
25 Diethyl phthalate	150 g
Acetone	2 000 g
Ethanol	2 000 g

Tablets

Enteric coating layered pellets	100 g
Microcrystalline cellulose	300 g
Crospovidone	8 g
Sodium stearyl fumarate	1 g

30 The pellets covered with separating layer are produced as in Example 13.

The enteric coating layer is applied in a fluid bed from a acetone/ethanol solution. Enteric coating layered pellets and tablet excipients are mixed and compressed into tablets as described in Example 2.

5 Example 17

Core material

5	5-Carbomethoxy-6-methyl-2[[3,4-dimethoxy-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole	200 g
10	Sugar sphere seeds	200 g
	Hydroxypropyl cellulose	25 g
	Purified water	623 g

Separating layer

15	Core material	200 g
	Hydroxypropyl cellulose	20 g
	Talc	34 g
	Magnesium stearate	3 g
20	Purified water	457 g

Enteric coating layer

25	Pellets covered with separating layer	200 g
	Methacrylic acid copolymer	150 g
	Triethyl citrate	45 g
30	Mono- and diglycerides	8 g
	Polysorbate 80	1 g
	Purified water	250 g

Tablets

Enteric coating layered pellets	100 g
Microcrystalline cellulose	232 g
Sodium stearyl fumarate	1 g

- 30 Suspension layering is performed in a fluid bed apparatus using bottom spray technique. 5-Carbomethoxy-6-methyl-2[[3,4-dimethoxy-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole is sprayed onto sugar sphere seeds from a

water solution containing the dissolved binder.

The prepared core material is covered with separating layer in a fluid bed apparatus with a hydroxypropyl cellulose solution containing talc and
5 magnesium stearate. The enteric coating layer is sprayed as a water dispersion onto the pellets covered with separating layer in a fluid bed apparatus.

Enteric coating layered pellets and tablet excipients are mixed and compressed into tablets using a single punch tableting machine (Korsch EK0) using 11 mm
10 round punches. Tablet hardness measured on a Schleuniger hardness tester is determined to approx. 170 N.

15 Example 18

The same tableted dosage form as described in Example 17 is produced with (+)-5-carbomethoxy-6-methyl-2[[[(3,4-dimethoxy-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium as active substance.

20 The results from tests on acid resistance of the enteric coating layered pellets and the compressed tablets are disclosed in Table I, below.

25 Table I

Example No	Acid resistance, pellets (%)	Acid resistance, tablets (%)
1	95	93
10	95	86

Comments:

Surprisingly, the acid resistance, tablets, shows that the enteric coating layer according to
30 the present invention sufficiently withstands compression.

Reference example ITablets

5	Omeprazole enteric coating layered pellets	180 g
	Microcrystalline cellulose	219 g
	Sodium stearyl fumarate	1 g

10 Omeprazole pellets from Losec® 40 mg capsules are mixed with microcrystalline cellulose and sodium stearyl fumarate and compressed into tablets using a single punch tabletting machine. The Vickers hardness on the enteric coating layered pellets is measured to a value of 22. The tablet tooling is round with a diameter of 10 mm. Punch force is set to 3.7 kN.

15

Reference example IITablets

20	Lansoprazole enteric coating layered pellets (content of Lanzo® 30 mg capsules)	276 g
	Microcrystalline cellulose	644 g

25 Lansoprazole pellets are mixed with microcrystalline cellulose and tableted in a single punch tabletting machine. The Vickers hardness on enteric coating layered pellets is measured to a value of 18. The tablet tooling is round with a diameter of 12 mm. Punch force is set to 3.6 kN.

Reference example III30 Core material

Magnesium omeprazole	15.0 kg
Sugar sphere seeds	15.0 kg
Hydroxypropyl methylcellulose	2.25 kg
Purified water	40 kg

35

Separating layer

Core material	15.0 kg
Hydroxypropyl cellulose	1.5 kg
Talc	2.57 kg
5 Magnesium stearate	0.21 kg
Purified water	30 kg

Enteric coating layer

- 10 Pellets covered with separating layer 200 g
 Enteric coating layer material is used as described in Drugs Made In Germany 37, No. 2 (1994), p.53, Table 1, Formulation no. 9.
 The amount of coating polymer as calculated in above reference is 40 % (w/w).

15 Over-coating layer

Enteric coating layered pellets	291 g
Hydroxypropyl methylcellulose	4 g
Magnesium stearate	0.2 g
Purified water	80 g

20

Tablets

Over-coating layered pellets	75 g
Microcrystalline cellulose	174 g
Sodium stearyl fumarate	0.6 g

25

- Suspension layering is performed in a fluid bed apparatus. Omeprazol magnesium is sprayed onto sugar sphere seeds from a water suspension containing the dissolved binder. The separating layer, enteric coating layer and the over-coating layer are sprayed onto pellets in a fluid bed apparatus. The over-coating layer is applied to prevent sticking of pellets before tableting. Over-coating layered pellets and tablet excipients are tableted as in Example 2. Upper punch force is set to 5 kN.

- 30 The results from tests on acid resistance of the enteric coating layered pellets and the compressed tablets are disclosed in Table II, below.

Table II

Reference example number	Acid resistance pellets (%)	Acid resistance tablets (%)
I	97	6
II	98	25
III	98	82

Comments:

5

As can be seen from the presented data, the enteric coating layer of the products studied, including the two marketed products (Reference examples I and II) do not possess the mechanical properties required to withstand compression into tablets.

10

Preparation of active substance

15 5-Fluoro-2[[[(4-cyclopropylmethoxy-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole magnesium and 5-carbomethoxy-6-methyl-2[[[(3,4-demethoxy-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole used in the examples are disclosed in WO 90/06925 and WO 91/19712, hereby incorporated as a whole by references. Some of the single enantiomers thereof are prepared in accordance with the following Examples A - E.

20 **Example A. Preparation of (+)-5-fluoro-2-[(4-cyclopropylmethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole**

25 The crude product of the diastereomers of a mixture of two regiosomeric mandelic esters, namely 5-fluoro-2-[(4-cyclopropylmethoxy-2-pyridinyl)methyl]-
(R/S)-sulfinyl]-1-[(R)-mandeloyloxymethyl]-1H-benzimidazole and 6-fluoro-2-
[[[(4-cyclopropylmethoxy-2-pyridinyl)methyl]-R/S-sulfinyl]-1-[(R)-
mandeloyloxymethyl]-1H-benzimidazole (5.0 g, 9.8 mmol) were divided into five
parts and each part was chromatographed on a reversed phase column (HPLC,
Kromasil C8) in order to separate the diastereomers. The stereo isomers were
30 easily separated by elution with a mixture of aqueous 0.1 M ammonium acetate
and acetonitrile (67.5/32.5). However each separated diastereomer consisted of a
mixture of the two regiosomers. These intermediates were used directly in their

solutions during the hydrolysis step. To the acetonitrile/aqueous solutions of the more lipophilic diastereomer were added 1 M aqueous solutions of NaOH until the pH was around 12-13. After 5 minutes the solutions were neutralized with 3.0 M aqueous solutions of NH₄Cl whereupon the solutions from each preparation
5 were combined and extracted with methylene chloride. The organic phases were dried over Na₂SO₄ and the solvents were removed by film evaporation. Addition of 30 ml of acetonitrile afforded the product to crystallize and after filtration there was obtained 260 mg (16%) of the title compound as white crystals, m.p. 152°-154°C. The optical purity (e.e.) which was analyzed by chiral column
10 chromatography was 99.2%. [a]²⁰_D= +208.6° (c=0.5%, chloroform).

Example B. Preparation of (+)-5-fluoro-2-[(4-cyclopropylmethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt

15 Magnesium (7.1 mg, 0.29 mmol) is dissolved and reacted with methanol at 40°C with a catalytic amount of methylene chloride. The reaction is run under nitrogen and is finished after two hours. (+)-5-Fluoro-2-[(4-cyclo-propylmethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (200 mg, 0.58 mmol) obtained as in Example A was added after the magnesium methoxide solution had been chilled
20 to room temperature. The mixture is stirred for two hours whereupon a small amount of water (0.05 ml) is added. After stirring another hour the small amount of inorganic salts are filtered off. The solution is concentrated on a rotavapor until two ml of the solution is left. While chilling and stirring, water is added dropwise which afforded the product to precipitate. After filtration the product is washed
25 with a small amount of water and then dried in vacuum. There is obtained 97 mg (47%) of the title compound as a white powder. [a]²⁰_D= +191.3° (c=1.0%, DMSO).

Example C. Preparation of (+)-5-carbomethoxy-6-methyl-2-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole

30 The crude product of the diastereomers of a mixture of two regioisomeric mandelic esters, namely 5-carbomethoxy-6-methyl-2-[(3,4-dimethoxy-2-pyridinyl)methyl]-^(R/S)-sulfinyl]-1-[(R)-mandeloyloxymethyl]-1H-benzimidazole and 6-carbomethoxy-5-methyl-2-[(3,4-dimethoxy-2-pyridinyl)methyl]-^(R/S)-sulfinyl]-1-[(R)-mandeloyloxymethyl]-1H-benzimidazole (1.8 g, 3.3 mmol) was divided into three parts. Each part was chromatographed on a reversed phase column (HPLC, Kromasil C8) in order to separate the diastereomers. The

- stereoisomers were easily separated by elution with a mixture of aqueous 0.1 M ammonium acetate and acetonitrile (70/30), but each separated diastereomer consisted of a mixture of the two regioisomers. These intermediates were used directly in their solutions during the hydrolyses; To the acetonitrile/aqueous
- 5 solutions of the more lipophilic diastereomer were added 1 M aqueous solutions of NaOH until the pH was around 12-13. After 5 minutes the solutions were neutralized with 3.0 M aqueous solutions of NH₄Cl. The solutions from each preparation were combined and extracted with methylenechloride whereupon the organic phases were dried over Na₂SO₄. Removal of the solvents and flash
- 10 chromatography of the residue (silica gel, methanol-methylenechloride gradient 1-8%) yielded 250 mg of a yellow oil. The product was crystallised by adding acetonitrile (3 ml) and after filtration there was obtained 210 mg (32%) of the title compound as white crystals m.p. 171-173° C. [a]²⁰ D= +153.1° (c=0.5%, chloroform).
- 15
- Example D. Preparation of (+)-5-carbomethoxy-6-methyl-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole sodium salt
- To a mixture of (+)-5-carbomethoxy-6-methyl-2-[(3,4-dimethoxy-2-pyridinyl)-
- 20 methylsulfinyl]-1H-benzimidazole (200 mg, 0.51 mmol) and ethanol (10 ml) was added an aqueous solution of 2.0 M NaOH (0.26 ml, 0.51 mmol). The solvent was removed by film evaporation whereupon the residue was dissolved in 2-butanone (1 ml). Toluene (5 ml) was added dropwise while stirring. The formed precipitate was removed by centrifugation and washed with diethyl ether. There was
- 25 obtained 170 mg (81%) of the title compound as white crystals m. p. (decomp.) 170°-173°C. [a]²⁰ D= +93.6°(c=1%, methanol).
- Example E. Preparation of (+)-5-carbomethoxy-6-methyl-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole magnesium salt
- 30
- (+)-5-Carbomethoxy-6-methyl-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole sodium salt (100 mg, 0.24 mmol) obtained as in Example D is dissolved in water (2 ml) and MgCl₂·6H₂O (25 mg, 0.12 mmol) dissolved in water (1 ml) is added dropwise. The formed precipitate is isolated by
- 35 centrifugation and ished with water. The product is dried in a desiccator and there is obtained 84 mg (87%) of a white powder. [a]²⁰ D= + 170° (c=0.5%, DMSO).

CLAIMS

1. An oral pharmaceutical multiple unit tableted dosage form comprising tablet excipients and individually enteric coating layered units of a core material containing active substance in the form of 5-fluoro-2[[(4-cyclopropylmethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or 5-carbomethoxy-6-methyl-2[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or one of its single enantiomers or an alkaline salt thereof, optionally mixed with alkaline compounds, covered with one or more layer(s) of which at least one is an enteric coating layer, whereby the enteric coating layer has mechanical properties such that the compression of the individual units mixed with the tablet excipients into the multiple unit tableted dosage form does not significantly affect the acid resistance of the individually enteric coating layered units.
- 15 2. A tableted dosage form according to claim 1, wherein the active substance is 5-fluoro-2[[(4-cyclopropylmethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or one of its single enantiomers or an alkaline salt thereof.
- 20 3. A tableted dosage form according to claim 1, wherein the active substance is 5-carbomethoxy-6-methyl-2[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or one of its single enantiomers or an alkaline salt thereof.
- 25 4. A tableted dosage form according to claim 1, wherein the acid resistance of the individually enteric coating layered units is in coherence with the requirements on enteric coated articles defined in the United States Pharmacopeia.
- 30 5. A tableted dosage form according to claim 1, wherein the acid resistance of the individually enteric coating layered units does not decrease more than 10 % during the compression of the individual units into the multiple unit tableted dosage form.

6. A tableted dosage form according to claim 1, wherein the enteric coating layer covering the individual units comprises a plasticized enteric coating layer material.

5

7. A tableted dosage form according to claim 1, wherein the enteric coating layer covering the individual units has a thickness of at least 10 µm.

8. A tableted dosage form according to claim 1, wherein the individually enteric
10 coating layered units are further covered with an over-coating layer comprising pharmaceutically acceptable excipients.

9. A tableted dosage form according to claim 1, wherein the dosage form is divisible.

15

10. A tableted dosage form according to claim 1, wherein the dosage form is dispersible to a suspension of individually enteric coating layered units in an aqueous liquid.

20 11. A tableted dosage form according to claim 1, wherein an optionally applied separating layer(s) comprises pharmaceutically acceptable excipients which are soluble, or insoluble but disintegrating in water, and optionally alkaline compounds.

25 12. A tableted dosage form according to claim 1, wherein the core material is a seed layered with the active substance.

13. A tableted dosage form according to claim 12, wherein the seeds have a size of 0.1 - 2 mm.

30

14. A process for the manufacture of a pharmaceutical multiple unit tableted dosage form comprising tablet excipients and individually enteric coating layered units of a core material containing active substance as defined in claim 1, optionally mixed with alkaline compounds, wherein the core material is
5 optionally covered with one or more separating layer(s) and further covered with one or more enteric coating layer(s), whereafter the individually enteric coating layered units are mixed with tablet excipients and compressed into a tablet, and whereby the enteric coating layer has mechanical properties such that the compression of the individual units with the tablet excipients into the multiple
10 unit tableted dosage form does not significantly affect the acid resistance of the individually enteric coating layered units.
15. A process according to claim 14, wherein the individually enteric coating layered units are further coated with an over-coating layer before compression of
15 the individual units into the multiple unit tableted dosage form.
16. A tableted dosage form according to any of claims 1 to 13 for use in therapy.
17. A tableted dosage form according to any of claims 1 to 13 for use in inhibiting
20 gastric acid secretion in mammals and man.
18. A tableted dosage form according to any of claims 1 to 13 for use in the treatment of gastrointestinal inflammatory diseases in mammals and man.
- 25 19. A method for inhibiting gastric acid secretion in mammals and man by administering to a host in need thereof a therapeutically effective dose of a multiple unit tableted dosage form according to any of claims 1 to 13.
- 30 20. A method for the treatment of gastrointestinal inflammatory diseases in mammals and man by administering to a host in need thereof a therapeutically effective dose of a multiple unit tableted dosage form according to any of claims

1 to 13.

21. A press-through blister package comprising a multiple unit tableted dosage form according to any of claims 1 to 13.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00680

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 9/26, A61K 9/20, A61K 31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EMBASE, MEDLINE, WPI, WPIL, CLAIMS, CA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0247983 A2 (AKTIEBOLAGET HÄSSLE), 2 December 1987 (02.12.87), page 5, line 6 - page 9, line 12, examples --	1-18,21
X	EP 0519144 A1 (ILSAN ILAC VE HAMMADDELERİ SANAYI A.S.), 23 December 1992 (23.12.92) --	1-18,21
A	EP 0365947 A1 (PHARMACIA AB), 2 May 1990 (02.05.90), page 3, line 37 - line 55 --	1-18,21
A	WO 9222284 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 23 December 1992 (23.12.92) -- -----	1-18,21

 Further documents are listed in the continuation of Box C. See patent family annex.

- * Special categories of cited documents
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

13 October 1995

Date of mailing of the international search report

21.10.1995

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Anneli Jönsson
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00680

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 19-20
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.


INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/SE 95/00680

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A2- 0247983	02/12/87	SE-T3- 0247983 AU-B- 601974 AU-A- 7191287 CA-A- 1292693 DE-A- 3783394 DK-B- 169988 EP-A,A,A 0496437 EP-A,A- 0567201 ES-T- 2006457 GB-A- 2189698 HK-A- 135294 IE-B- 61416 JP-C- 1863556 JP-A- 5294831 JP-A- 62258320 NO-B,C- 174239 SU-A- 1820837 US-A- 4786505		27/09/90 05/11/87 03/12/91 18/02/93 24/04/95 29/07/92 27/10/93 01/01/94 04/11/87 09/12/94 02/11/94 08/08/94 09/11/93 10/11/87 27/12/93 07/06/93 22/11/88
EP-A1- 0519144	23/12/92	NONE		
EP-A1- 0365947	02/05/90	SE-T3- 0365947 AU-B- 612525 AU-A- 4365089 CA-A- 2000932 DE-T- 68907177 ES-T- 2055775 HK-A- 123394 JP-A- 2164821 SE-A- 8803822 US-A- 5178868		11/07/91 03/05/90 26/04/90 13/01/94 01/09/94 18/11/94 25/06/90 26/10/88 12/01/93
WO-A1- 9222284	23/12/92	AU-A- 1974692 BG-A- 98286 CN-A- 1067809 CZ-A- 9302764 DE-A- 4219390 EP-A- 0519365 EP-A- 0589981 FI-D- 935677 JP-T- 6508118 NO-A,D- 934648		12/01/93 15/08/94 13/01/93 13/07/94 24/12/92 23/12/92 06/04/94 00/00/00 14/09/94 16/12/93

IDS REFERENCES



FOR

PCT

WORLD INTELLECTUAL PROPERTY
International Bu



INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9607421A2

(51) International Patent Classification ⁶ : A61K 38/18 // (A61K 38/18, 31:44)		A2	(11) International Publication Number: WO 9607421
			(43) International Publication Date: 14 March 1996 (14.03.96)
<p>(21) International Application Number: PCT/JP95/01772</p> <p>(22) International Filing Date: 6 September 1995 (06.09.95)</p> <p>(30) Priority Data: 6/215717 9 September 1994 (09.09.94) JP</p> <p>(71) Applicant (<i>for all designated States except US</i>): TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (<i>for US only</i>): SATOH, Hiroshi [JP/JP]; 6-1-616, Satsukigaoka-minami, Suita-shi, Osaka 565 (JP).</p> <p>(74) Agents: ASAHIKA, Tadao et al.; Osaka Plant of Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532 (JP).</p>			<p>(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: AN ANTIULCER MEDICINE COMPRISING A PROTEIN POSSESSING CELL GROWTH FACTOR ACTIVITY AND A PROTON PUMP INHIBITOR</p> <p>(57) Abstract</p> <p>The present invention relates to a medicine which comprises a combination of a protein possessing cell growth factor activity with a proton pump inhibitor which enhances the preventive and therapeutic effect of either drug used alone against ulcers, particularly peptic ulcers.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DESCRIPTION

AN ANTIULCER MEDICINE COMPRISING A PROTEIN POSSESSING CELL GROWTH FACTOR ACTIVITY AND A PROTON PUMP INHIBITOR5 Technical Field

The present invention relates to a medicine which comprises a combination of a protein possessing cell growth factor activity with a proton pump inhibitor. More specifically, the present invention relates to an antiulcer medicine effective in the prevention and treatment of 10 ulcers, particularly peptic ulcers in mammals.

Background Art

15 Ulcers occur by various causes. Peptic ulcers are thought to occur due to deterioration of the balance between aggressive factors (factors that adversely affect the gastrointestinal mucosal membrane), such as gastric juice, pepsin, bile and food, and protective factors, such as mucosal membrane blood flow, mucus secretion and 20 carbonate ion secretion. Based on this idea, there is need for peptic ulcer therapy involving the suppression of aggressive factors or enhancement of protective factors; many drugs exhibiting such actions have been developed and are now in wide use.

25 Well-known aggressive factor suppressors are acid secretion suppressors, such as histamine H₂ receptor blockers (e.g., cimetidine, ranitidine, famotidine, loxatidine), muscarine receptor blockers (e.g. pirenzepine) and proton pump inhibitors (e.g. omeprazole, lansoprazole).

30 On the other hand, well-known protective factor enhancers include prostaglandin derivatives (e.g., misoprostol, ornoprostil) and sucralfate.

35 Thanks to the development of these drugs, the prevention and treatment of upper gastrointestinal tract ulcerative and inflammatory lesions, such as reflux

esophagitis, gastritis, gastric ulcer, duodenal ulcer and anastomotic ulcer, have recently improved significantly.

However, intractable ulcers remain refractory to treat using these drugs. Ulcerative lesions caused by oral intake of non-steroidal anti-inflammatory agents, such as indomethacin and aspirin, pose another major problem as intractable diseases. In addition, it is known that ulcers, even once healed with the above-described drugs, often recur after medication is discontinued. There is need for new drugs or advanced therapies offering solutions to these problems. The suppressors and enhancers are thought to indirectly promote ulcer healing by providing favorable healing conditions, rather than by directly promoting mucosal cell growth. In recent years, various growth factors have been found to play a key role in the healing of wounds, including those in the gastrointestinal mucosa; for example, acidic and basic fibroblast growth factors and miteins thereof promote the healing of digestive ulcers (Folkman J. et al.: Annals of Surgery 214, 414-427(1991), Fitzpatrick L.R. et al.: Digestion 53, 17-27(1992), Konturek S.J. et al.: Gut 34, 881-887(1993), Szabo S. et al.: Gastroenterology 106, 1106-1111(1994), Satoh H. et al.: Gastroenterology 100, A155(1991) and Gastroenterology 102, A159(1992)). As concerns the mechanism of action of these factors, it has been suggested that they exhibit almost no inhibition of aggressive factors and no enhancement of protective factors, but positively promote ulcer healing by, for example, promoting angiogenesis in the ulcer base, resulting in decreased ulcer recurrence rates (Gastroenterology 102, A159(1992)).


Disclosure of Invention

Through investigations using a rat model of aspirin-induced gastric ulcer, the present inventors found that when a proton pump inhibitor and a fibroblast growth factor are used in combination, the antiulcer effect is definitely

better than with either drug alone. The inventors made further investigations based on this finding, and developed the present invention.

Accordingly, the present invention relates to:

- 5 (1) A medicine which comprises a combination of a protein possessing cell growth factor activity with a proton pump inhibitor,
- 10 (2) A medicine of term (1) above, wherein the protein possessing cell growth factor activity is a protein possessing fibroblast growth factor activity,
- 15 (3) A medicine of term (2) above, wherein the protein possessing fibroblast growth factor activity is a protein possessing basic fibroblast growth factor activity,
- 20 (4) A medicine of term (3) above, wherein the protein possessing basic fibroblast growth factor activity is acid-resistant,
- 25 (5) A medicine of term (3) above, wherein the protein possessing basic fibroblast growth factor activity is a basic fibroblast growth factor (bFGF) mutein showing enhanced acid stability as a result of replacement of at least one bFGF-constituent cysteine with another amino acid,
- 30 (6) A medicine of term (5) above, the bFGF mutein is the recombinant human bFGF mutein CS23 in which cysteine residues at the 70- and 88- positions are replaced by serine residues,
- 35 (7) A medicine of term (1) above, wherein the proton pump inhibitor is a benzimidazole compound,
- 40 (8) A medicine of term (7) above, wherein the benzimidazole compound is a compound of the formula:



wherein ring A may optionally be substituted, R¹, R³ and R⁴ are, the same or different, hydrogen, or an alkyl or alkoxy group, R² is a hydrocarbon group which may optionally be substituted, and n is 0 or 1, or a salt thereof,

5 (9) A medicine of term (8) above, wherein the compound is lansoprazole,

(10) A medicine of term (1) above, which comprises a combination of the mutoein CS23 with lansoprazole,

10 (11) A medicine of term (1) above, which is used to prevent or treat an ulcer,

(12) A medicine of term (11) above, wherein the ulcer is a peptic ulcer,

15 (13) A medicine of term (1), which is a kit which comprises a protein possessing cell growth factor activity and a proton pump inhibitor,

(14) A medicine of term (1), which is a pharmaceutical composition which comprises a protein possessing cell growth factor activity and a proton pump inhibitor,

20 (15) A method of producing a pharmaceutical composition which comprises admixing a protein possessing cell growth factor activity with a proton pump inhibitor,

(16) Use of a combination of a protein possessing cell growth factor activity with a proton pump inhibitor for the manufacture of a medicine for the prevention or treatment 25 of an ulcerative disease,

(17) A method for preventing or treating a ulcerative disease of a mammal, which comprises administering an effective amount of a protein possessing cell growth factor activity in combination with an effective amount of a proton pump inhibitor to the mammal, and

30 (18) A method of use of a proton pump inhibitor for enhancing a protein possessing cell growth factor activity.

A cell growth factor is defined as a non-nutrient substance that promotes animal cell growth *in vivo* or *in vitro*; the term "protein possessing cell growth factor"

activity" as used herein includes all proteins possessing such activity, as long as they are of low toxicity. Examples of such cell growth factors include fibroblast growth factor (FGF), platelet-derived growth factor (PDGF),
5 epithelial cell growth factor (EGF), α - and β -transforming growth factors (TGF α , TGF β), insulin-like growth factor (IGF) and platelet-derived angiogenesis factor (PD-ECGF). These proteins possessing cell growth factor activity may be isolated from animal bodies and purified, or produced by
10 gene engineering, and as long as they retain their cell growth factor activity, may be muteins resulting from appropriate modifications of constituent amino acids of natural proteins, such as deletion and replacement of some constituent amino acids, and addition of other amino acids.

15 Proteins possessing fibroblast growth factor (FGF) activity include proteins possessing acidic fibroblast growth factor (aFGF) activity and proteins possessing basic fibroblast growth factor (bFGF) activity, with preference given to proteins possessing bFGF activity.

20 Proteins possessing bFGF activity is preferably acid-resistant.


Proteins possessing fibroblast growth factor (FGF) activity include acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), and muteins thereof.
25 Example bFGF muteins include those described in Japanese Patent Unexamined Publication No. 193/1990 and Japanese Publication of translations of International patent application No. 505736/1991. Preferable muteins are (1) muteins resulting from replacement of at least one bFGF-
30 constituting amino acid with another amino acid, (2) the muteins of term (1) above, wherein said bFGF-constituting amino acid is cysteine, (3) the muteins of term (1) above, wherein said other amino acid is a neutral amino acid, and (4) the muteins of term (1) above, wherein at least one cysteine, as a constituent amino acid, is replaced with serine. For example, the muteins include a modified bFGF

such as a purified recombinant human basic FGF (rhbFGF) protein in which a mutation is induced by changing one or more of the four cysteines present at amino acid residues 25, 69, 87 and 92 of the mature protein to serine. In 5 numbering the human bFGF-constituent amino acids, the N-terminal Pro comprises the first amino acid. Of these muteins, those showing enhanced acid stability, in comparison with the natural basic fibroblast growth factor, as a result of replacement of at least one bFGF- 10 constituting cysteine with another amino acid, are preferred, with greater preference given to the mutein (CS23) resulting from serine replacement of the cysteine residues (70- and 88-positions) at the second and third positions from the N-terminal side, among the four cysteine 15 residues in the amino acid sequence of human bFGF. The structure of the mutein CS23 is more fully described in Senoo et al., Biochemical and Biophysical Communications, Vol.151, No.2, 702-708 (1988) and in EP-281,822.

20 The term proton pump inhibitor as used herein is defined as a drug that suppresses acid secretion by directly or indirectly inhibiting H/K-ATPase, which functions as a proton pump in gastric mucosal acid secreting cells (parietal cells). Examples of such drugs 25 include omeprazole, lansoprazole, pantoprazole, pariprazole sodium, leminoprazole, TY-11345, TU-199, FPL-65372, BY-686, Tannic acid, Ellagic acid, Ebselen, AHR-9294, Cassigarol-A, Bafilomycin, Y-25942, Xanthoangelol E, SK&F-96356, (-)-Epigallocatechin gallate, WY-27198, T-330 and KF-20054.

30 Especially, proton pump inhibitors include benzimidazole compounds, which possess proton pump inhibitory activities and are of low toxicity. Preferable benzimidazole compounds include 2-[(pyridyl)-methylsulfinyl or -methylthio]benzimidazole derivatives and salts thereof. 35 A compound (or salt thereof) represented by formula (I) below is more preferred.

5



wherein ring A may optionally be substituted; R_b is a hydrogen atom, an alkyl group, an acyl group, a carboalkoxy group, a carbamoyl group, an alkylcarbamoyl group, a dialkylcarbamoyl group or an alkylsulfonyl group; R_c, R_e, and R_f are, the same or different, a hydrogen atom, an alkyl group, an alkoxy group or an alkoxyalkoxy group; R_d is a hydrogen atom, an alkyl group or a group represented by -OR_f in which R_f represents a hydrocarbon group which may optionally be substituted; q is 0 or 1.

15 Benzimidazole compounds above are described in USP 4,045,563, USP 4,255,431, USP 4,359,465, USP 4,472,409, USP 4,508,905, JP-A-59181277, USP 4,628,098, USP 4,738,975, USP 5,045,321, USP 4,786,505, USP 4,853,230, USP 5,045,552, EP-A-295603, USP 5,312,824, EP-A-166287, EP-A- 519365, and other publications.

20 With respect to formula (I) above, the substituent that may optionally be present on ring A includes halogen atoms, alkyl groups which may be substituted for, cycloalkyl groups which may be substituted for, alkenyl groups which may be substituted for, alkoxy groups which may be substituted for, cyano groups, carboxy groups, carboalkoxy groups, carboalkoxyalkyl groups, carbamoyl groups, carbamoylalkyl groups, hydroxy groups, hydroxyalkyl groups, acyl groups, carbamoyloxy groups, nitro groups, acyloxy groups, aryl groups, aryloxy groups, alkylthio groups and alkylsulfinyl groups, and the like.

25 The above substituents are hereinafter described.
30 Halogen atoms include fluorine, chlorine, bromine and iodine. Fluorine and chlorine are preferred, with greater preference given to fluorine.

The alkyl group in the alkyl group which may be substituted is exemplified by straight-chain or branched alkyl groups having 1 to 10 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, 5 tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl). Straight-chain or branched alkyl groups having 1 to 6 carbon atoms are preferred, with greater preference given to straight-chain or branched alkyl groups having 1 to 3 carbon atoms. Substituents on 10 the substituted alkyl group include halogens, nitro, cyano groups, hydroxy groups, carboxy groups, amidino groups, guanidino groups, carbamoyl groups, amino groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like.

15 The cycloalkyl group in the cycloalkyl group which may be substituted is exemplified by cycloalkyl groups having 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl etc.. The cycloalkyl group may be substituted by, for example, 20 halogens, nitro, cyano groups, hydroxy groups, carboxy groups, amidino groups, guanidino groups, carbamoyl groups, amino groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like.

25 The alkenyl group in the alkenyl group which may be substituted is exemplified by straight-chain or branched alkenyl groups having 2 to 16 carbon atoms. Such alkenyl groups include allyl, vinyl, crotyl, 2-penten-1-yl, 3-penten-1-yl, 2-hexen-1-yl, 3-hexen-1-yl, 2-methyl-2-propen-1-yl and 3-methyl-2-buten-1-yl. Straight-chain or branched 30 alkenyl groups having 2 to 6 carbon atoms are preferred, with greater preference given to straight-chain or branched alkenyl groups having 2 to 4 carbon atoms. The alkenyl group may be substituted by, for example, halogens, nitro, cyano groups, amidino groups, guanidino groups amino 35 groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like . The alkenyl group

mentioned above includes isomers (E- and Z-configurations) with respect to double bond.

The alkoxy group in the alkoxy group which may be substituted is exemplified by alkoxy groups having 1 to 10 carbon atoms. Such alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, cyclobutoxy, cyclopentoxy and cyclohexyloxy. Alkoxy groups having 1 to 6 carbon atoms are preferred, with greater preference given to alkoxy groups having 1 to 3 carbon atoms. The alkoxy group may be substituted by, for example, halogens, nitro, amidino groups, guanidino groups amino groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like.

The halogen as a substituent on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is exemplified by chlorine, bromine, fluorine and iodine.

The alkyl group in the alkylamino group as a substituent on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is preferably exemplified by straight-chain or branched alkyl groups having 1 to 6 carbon atoms. Such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, isopentyl, n-hexyl and isohexyl. Among others, straight-chain or branched alkyl groups having 1 to 4 carbon atoms are preferred.

The acyl group in the acylamino group as a substituent on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is exemplified by acyl groups derived from organic carboxylic acids, with preference given to alkanoyl groups having 1 to 6 carbon atoms. Such alkanoyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl and hexanoyl, with greater preference given to alkanoyl groups having 1 to 4 carbon atoms.

The number of substituents on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is 1 to 6, preferably 1 to 3.

The substituted alkyl groups include trifluoromethyl,
5 trifluoroethyl, difluoromethyl, trichloromethyl,
hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl,
methoxyethyl, ethoxyethyl, 1-methoxyethyl, 2-methoxyethyl,
2,2-dimethoxyethyl, 2,2-diethoxyethyl and 2-
diethylphosphorylethyl, among others. Difluoromethyl,
10 trifluoromethyl and hydroxymethyl are preferred, with
greater preference given to trifluoromethyl.

The substituted cycloalkyl groups include 2-
aminocyclopropan-1-yl, 4-hydroxycyclopentan-1-yl and 2,2-
difluorocyclopentan-1-yl, among others.

15 The substituted alkenyl groups include 2,2-
dichlorovinyl, 3-hydroxy-2-propen-1-yl and 2-methoxyvinyl,
among others.

20 The substituted alkoxy groups include difluoromethoxy,
trifluoromethoxy, 2,2,2-trifluoroethoxy, 2-methoxyethoxy,
4-chlorobenzylxy and 2-(3,4-dimethoxyphenyl)ethoxy, among
others. Difluoromethoxy is preferred.

25 The alkoxy group in the carboalkoxy group is
exemplified by alkoxy groups having 1 to 7 carbon atoms
(e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy,
isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy,
neopentoxy, hexyloxy, heptyloxy).

30 The alkoxy group in the carboalkoxyalkyl group is
exemplified by alkoxy groups having 1 to 4 carbon atoms
(e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy,
isobutoxy, sec-butoxy, tert-butoxy). The alkyl group in
the carboalkoxyalkyl group is exemplified by alkyl groups
having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl). Such
carboalkoxyalkyl groups include carbomethoxymethyl, 2-
35 carbomethoxyethyl, 2-carbomethoxypropyl, carboethoxymethyl,

2-carboethoxyethyl, 1-carbomethoxypropyl, carbopropoxymethyl and carbobutoxymethyl.

The alkyl group in the carbamoylalkyl group is exemplified by alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, 5 isobutyl, sec-butyl, tert-butyl).

The alkyl group in the hydroxyalkyl group is exemplified by alkyl groups having 1 to 7 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, 10 isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl).

The acyl group as such or the acyl group in the acyloxy group is exemplified by alkanoyl groups having 1 to 4 carbon atoms such as formyl, acetyl, propionyl, butyryl 15 and isobutyryl.

The aryl group as such or the aryl group in the aryloxy group is exemplified by aryl groups having 6 to 12 carbon atoms (e.g., phenyl, naphthyl).

The alkyl in the alkylthio group or alkylsulfinyl 20 group is exemplified by alkyl groups having 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl).

The number of substituents on substituted ring A is 25 preferably 1 to 4, more preferably 1 to 2. Such substituents on the benzene ring may be present at 4- and 5-positions, with preference given to 5-position.

Ring A is preferably A ring which may optionally be substituted by i) a halogen atom ii), an alkyl group which 30 may be substituted, iii) a cycloalkyl group which may be substituted, iv) an alkenyl group which may be substituted, or v) an alkoxy group which may be substituted.

The alkyl group for R^b is exemplified by alkyl groups having 1 to 5 carbon atoms (e.g., methyl, ethyl, n-propyl, 35 isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl). The acyl group for R^b is

exemplified by acyl groups having 1 to 4 carbon atoms, such as alkanoyl groups having 1 to 4 carbon atoms. The alkoxy in the carboalkoxy group is exemplified by alkoxy groups having 1 to 4 carbon atoms (e.g., formyl, acetyl, 5 propionyl, butyryl, isobutyryl). The alkyl in the alkylcarbamoyl group and dialkylcarbamoyl group is exemplified by alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, 10 isobutyl, sec-butyl, tert-butyl). The alkyl in the alkylsulfonyl group is exemplified by the above-mentioned alkyl groups having 1 to 4 carbon atoms. R^b is preferably hydrogen.

The alkyl group for R^c, R^e or R^g is exemplified by straight-chain or branched alkyl groups having 1 to 10 15 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl). Straight-chain or branched alkyl groups having 1 to 6 20 carbon atoms are preferred, with greater preference given to straight-chain or branched alkyl groups having 1 to 3 carbon atoms.

The alkoxy group for R^c, R^e or R^g is exemplified by alkoxy groups having 1 to 10 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec- 25 butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, octyloxy, nonyloxy). Alkoxy groups having 1 to 6 carbon atoms are preferred, with greater preference given to alkoxy groups having 1 to 3 carbon atoms.

30 The alkoxy in the alkoxyalkoxy group for R^c, R^e or R^g is exemplified by alkoxy groups having 1 to 4 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy).

R^c is preferably a hydrogen atom, an alkyl group or an 35 alkoxy group. R^e is preferably a hydrogen atom, an alkyl

group or an alkoxy group. R₉ is preferably a hydrogen atom.

The alkyl group for R_d is exemplified by alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, 5 isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl).

The hydrocarbon group in the hydrocarbon group which may optimally be substituted, for R_f, is exemplified by hydrocarbon groups having 1 to 13 carbon atoms, such as straight-chain or branched alkyl groups having 1 to 6 10 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl, isopentyl, hexyl), alkenyl groups having 2 to 6 carbon atoms (e.g., vinyl, allyl, 2-butenyl, methylallyl, 3-butenyl, 2-pentenyl, 4-pentenyl, 5-hexenyl), alkinyl groups having 2 to 6 carbon 15 atoms (e.g., ethynyl, propargyl, 2-butyn-1-yl, 3-butyn-2-yl, 1-pentyn-3-yl, 3-pentyn-1-yl, 4-pentyn-2-yl, 3-hexyn-1-yl), cycloalkyl groups having 3 to 6 carbon atoms (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), cycloalkenyl groups having 3 to 6 carbon atoms (e.g., 20 cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl), aralkyl groups having 7 to 13 carbon atoms (e.g., benzyl, 1-phenetyl, 2-phenetyl) and aryl groups having 6 to 10 carbon atoms (e.g., phenyl, naphthyl). Straight-chain or branched alkyl groups having 25 1 to 6 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl, isopentyl, hexyl) are preferred, with greater preference given to straight-chain or branched alkyl groups having 1 to 4 carbon atoms.

30 The substituent group in the substituted hydrocarbon group is exemplified by C₆₋₁₀ aryl groups (e.g., phenyl, naphthyl), amino, C₁₋₆ alkylamino groups (e.g., methylamino, ethylamino, isopropylamino), di-C₁₋₆ alkylamino groups (e.g., dimethylamino, diethylamino), N- 35 aralkyl-N-cycloalkylamino groups (e.g., N-benzyl-N-cyclohexylamino), N-aralkyl-N-alkylamino groups (e.g., N-

(1-naphthylmethyl)-N-ethylamino), azide, nitro, halogens (e.g., fluorine, chlorine, bromine, iodine), hydroxyl, C₁₋₄ alkoxy groups (e.g., methoxy, ethoxy, propoxy, butoxy), C₆₋₁₀ aryloxy groups (e.g., phenoxy, naphthoxy), C₁₋₆ alkylthio groups (e.g., methylthio, ethylthio, propylthio), C₆₋₁₀ arylthio groups (e.g., phenylthio, naphthylthio), cyano, carbamoyl groups, carboxyl groups, C₁₋₄ alkoxycarbonyl groups (e.g., methoxycarbonyl, ethoxycarbonyl), C₇₋₁₁ aryloxycarbonyl groups (e.g., phenoxycarbonyl, 1-naphthyoxy carbonyl, 2-naphthyoxy carbonyl), carboxy-C₁₋₄ alkoxy groups (e.g., carboxymethoxy, 2-carboxyethoxy), C₁₋₆ alkanoyl groups (e.g., formyl, acetyl, propionyl, isopropionyl, butyryl, pentanoyl, hexanoyl), C₇₋₁₁ alloyl groups (e.g., benzoyl, 1-naphthoyl, 2-naphthoyl), C₆₋₁₀ arylsulfonyl groups (e.g., benzenesulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl), C₁₋₆ alkylsulfinyl groups (e.g., methylsulfinyl, ethylsulfinyl), C₆₋₁₀ arylsulfinyl groups (e.g., benzenesulfinyl, 1-naphthylsulfinyl, 2-naphthylsulfinyl), C₁₋₆ alkylsulfonyl groups (e.g., methylsulfonyl, ethylsulfonyl), 5- or 6-membered heterocyclic groups (e.g., 2-furyl, 2-thienyl, 4-thiazolyl, 4-imidazolyl, 4-pyridyl, 1,3,4-thiadiazol-2-yl, 1-methyl-5-tetrazolyl) containing 1 to 4 hetero atoms (e.g., nitrogen, oxygen, sulfur), 5- or 25 6-membered heterocyclic carbonyl groups (e.g., 2-furoyl, 2-thienoyl, nicotinoyl, isonicotinoyl) containing 1 to 4 hetero atoms (e.g., nitrogen, oxygen, sulfur), 5- or 6-membered heterocyclic thio groups (e.g., 4-pyridylthio, 2-pyrimidylthio, 1,3,4-thiadiazol-2-ylthio, 1-methyl-5-tetrazolylthio) containing 1 to 4 hetero atoms (e.g., nitrogen, oxygen, sulfur). The heterocyclic thio group may condense with the benzene ring to form a bicyclic condensed thio group (e.g., 2-benzothiazolylthio, 8-quinolylthio). Halogens (e.g., fluorine, chlorine, bromine, iodine), 30 hydroxyl and C₁₋₄ alkoxy groups (e.g., methoxy, ethoxy, propoxy, butoxy) are preferred.


The number of substituents is normally 1 to 5, preferably 1 to 3.

- R^d is preferably an alkoxy group which may be substituted, or an alkoxyalkoxy group which may be substituted. The alkoxy in the alkoxy group which may be substituted is exemplified by alkoxy groups having 1 to 8 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, octyloxy).
- 10 The alkoxy in the alkoxyalkoxy group which may be substituted is exemplified by alkoxy groups having 1 to 4 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy). R^d is more preferably an alkoxy group having 1 to 8, preferably 1 to 4 carbon atoms, which may be halogenated, or an alkoxyalkoxy group which may be halogenated. Preferred alkoxy groups which may be halogenated include 2,2,2-trifluoroethoxy, 2,2,3,3,3-pentafluoropropoxy, 1-(trifluoromethyl)-2,2,2-trifluoroethoxy, 2,2,3,3-tetrafluoropropoxy, 2,2,3,3,4,4,4-heptafluorobutoxy, 2,2,3,3,4,4,5,5-octafluoropentoxy and methoxy. Preferred alkoxyalkoxy groups which may be halogenated include 3-methoxypropoxy.
- 15
- 20
- 25

q is preferably 0.

- More specifically, the benzimidazole compound for the present invention is exemplified by a compound represented by formula (II):

30



35

wherein ring A may optionally be substituted; R¹, R³ and R⁴ are, the same or different, hydrogen, or an alkyl or alkoxy group; R² is a hydrocarbon group which may optionally be substituted; n is 0 or 1.

With respect to formula (II) above, ring A is exemplified by the same rings as those mentioned for ring A of formula (I) above.

The alkyl group for R¹, R³ or R⁴ is exemplified by straight-chain or branched alkyl groups having 1 to 10 carbon atoms. Such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl and decyl. Straight-chain or branched alkyl groups having 1 to 6 carbon atoms are preferred, with greater preference given to straight-chain or branched alkyl groups having 1 to 3 carbon atoms.

The alkoxy group for R¹, R³ or R⁴ is exemplified by alkoxy groups having 1 to 10 carbon atoms. Such alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxyl, neopentoxyl, hexyloxy, heptyloxy, octyloxy, nonyloxy, cyclobutoxy, cyclopentoxy and cyclohexyloxy. Alkoxy groups having 1 to 6 carbon atoms are preferred, with greater preference given to alkoxy groups having 1 to 3 carbon atoms.

The hydrocarbon group which may optionally be substituted, for R², is exemplified by the same hydrocarbon groups as those mentioned for R⁶ above.

R¹ is preferably C₁₋₆ alkyl or C₁₋₆ alkoxy, more preferably C₁₋₃ alkyl.

R³ is preferably hydrogen or C₁₋₆ alky, more preferably hydrogen.

R² is preferably C₁₋₄ alkoxy which may optionally be substituted by i) halogen, ii) hydroxyl or iii) C₁₋₄ alkoxy, more preferably, C₁₋₃ alkyl which may optionally be substituted by i) halogen or ii) C₁₋₄ alkoxy.

R⁴ is preferably hydrogen.

Example benzimidazole compounds for the present invention include 2-[2-[3-methyl-4-(2,2,3,3-tetrafluoropropoxy)pyridyl]methylthio] benzimidazole, 2-[2-

- [3-methyl-4-(2,2,2-trifluoroethoxy)pyridyl]methylsulfinyl]benzimidazole (lansoprazole), 2-[(2-pyridyl)methylsulfinyl]benzimidazole (timoprazole), 2-[2-(3,5-dimethyl-4-methoxypyridyl)methylsulfinyl]-5-methoxy-1H-benzimidazole (omeprazole), sodium salt of 2-[2-[4-(3-methoxypropoxy)-3-methylpyridyl]methylsulfinyl]-1H-benzimidazole and 2-[2-(3,4-dimethoxy)pyridyl]methylsulfinyl]-5-difluoromethoxy-1H-benzimidazole (pantoprazole).
- 10 A benzimidazole compound (or salt thereof) for the present invention is produced by, for example, the above-described known methods described in Japanese or European Patent Publications and U.S. Patents, or modifications thereof.
- 15 The salt of a benzimidazole compound is preferably used as a physiologically acceptable salt. Physiologically acceptable salts include salts with inorganic bases, salts with organic bases and salts with basic amino acids. Useful inorganic bases include alkali metals (e.g., sodium, potassium) and alkaline earth metals (e.g., calcium, magnesium). Useful organic bases include trimethylamine, triethylamine, pyridine, picoline, N,N-dibenzylethylenediamine, ethanolamine, diethanolamine, trishydroxymethylaminomethane and dicyclohexylamine.
- 20 25 Useful basic amino acids include arginine and lysine. These salts are produced by known methods such as those described in EP-A-295603 and USP 4,738,974, or modifications thereof.
- The medicine of the present invention is applicable to the prevention and treatment of animal ulcers, and is particularly effective in the prevention and treatment of digestive ulcers in mammals, including humans. Examples of such digestive ulcers include gastric ulcer, duodenal ulcer, reflux esophagitis, anastomotic ulcer, acute and chronic gastritis.

The medicine of the present invention, characterized by combined use of a protein possessing cell growth factor activity and a proton pump inhibitor, is not subject to limitation as to dosage form. For example, a protein 5 possessing cell growth factor activity and a proton pump inhibitor may be prepared as individual preparations of ordinary dosage form, or as a composition incorporating both.

For an example of the medicine of the present 10 invention, a protein possessing cell growth factor activity (the active ingredient A) and a proton pump inhibitor (the active ingredient B) may be mixed to a single preparation, as desired, using pharmaceutically acceptable diluents, excipients and other additives by a known method of 15 pharmaceutical production. Each active ingredient may be prepared as a separate preparation, as desired, using pharmaceutically acceptable diluents, excipients and other additives. Alternatively, the medicine of the present invention may be prepared in a set (kit) in which each 20 component constitutes a separate preparation. For example, the medicine of the present invention can be used in a form of (1) a kit comprising a protein possessing cell growth factor activity and a proton pump inhibitor or (2) in a form of a composition containing a protein possessing cell 25 growth factor activity and a proton pump inhibitor.

As concerns the route of administration of the antiulcer medicine of the present invention, oral administration is preferable, but non-oral administrations 30 (e.g., intravenous administration, subcutaneous administration, intramuscular administration) are also possible. Proton pump inhibitors, in particular, permit both oral and non-oral administrations. Specifically, the route of administration is determined in consideration of 35 target ulcer site etc.

When a protein possessing cell growth factor activity and a proton pump inhibitor are used as separate preparations, they may be administered to the same individual at the same time or at time intervals via the 5 same route or different routes.

In administering the antiulcer medicine of the present invention, the protein possessing cell growth factor activity and the proton pump inhibitor can be administered in individual dosage forms prepared by conventional 10 methods. For proteins possessing cell growth factor activity, preparations in such dosage forms can, for example, be manufactured by the method described in Japanese Publication of translations of International patent application No. 505736/1991. Specifically, tablets 15 and capsules are prepared using pharmacologically acceptable carriers (e.g., lactose, corn starch, light silicic anhydride, microcrystalline cellulose, sucrose), binders (e.g., alpha-starch, methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, 20 hydroxypropylmethyl cellulose, polyvinylpyrrolidone), disintegrating agents (e.g., carboxymethyl cellulose, starch, low-substitutional hydroxypropyl cellulose), surfactants [e.g., Tween 80 (Kao-Atlas), Prullonic F68 (Asahi Denka, Japan), polyoxyethylene-polyoxypropylene 25 copolymer], antioxidants (e.g., L-cysteine, sodium sulfite, sodium ascorbate), lubricants (e.g., magnesium stearate, talc) and similar substances. An aqueous solution for injection is prepared by a conventional method using an aqueous solvent (e.g., distilled water, physiological 30 saline, Ringer's solution) or an oily solvent (e.g., sesame oil, olive oil). One or more than one additive can be used as necessary. Such additives include dissolution aids (e.g., sodium salicylate, sodium acetate), buffers (e.g., sodium citrate, glycerol), isotonizing agents (e.g., 35 glucose, inverted sugar), stabilizers (e.g., human serum albumin, polyethylene glycol), antiseptics (e.g., benzyl

alcohol, phenol) and analgesics (e.g., benzalkonium chloride, procaine hydrochloride). A solid preparation for injection is prepared by a conventional method using, for example, a diluent (e.g., distilled water, physiological saline, glucose), an activator (e.g., carboxymethyl cellulose, sodium alginate), an antiseptic (e.g., benzyl alcohol, phenol) and an analgesic (e.g., benzalkonium chloride, procaine hydrochloride).

In the case of proton pump inhibitors, the same method as above can normally be used. It is preferable, however, that the proton pump inhibitor be administered in the form of nucleated granules coated with a powder comprising the inhibitor and low-substitutional hydroxypropyl cellulose, according to the method described in Japanese Patent Application Unexamined Publication No. 301816/1988, or a solid composition stabilized with a stabilizer comprising a basic inorganic salt of magnesium and/or calcium, according to the method described in Japanese Patent Application Unexamined Publication No. 163018/1991.

Example compositions comprising a protein possessing cell growth factor activity and a proton pump inhibitor for oral administration include tablets, pills, granules, powders, capsules, syrups, emulsions and suspensions. These compositions are produced by known methods, using lactose, starch, sucrose, magnesium stearate and other substances as carriers or excipients.

Compositions for non-oral administration can be prepared as suppositories or external preparations.

Suppositories include rectal suppositories and vaginal suppositories. External preparations include ointments (including creams), vaginal preparations, transnasal preparations and percutaneous preparations.

For a suppository, a composition of the present invention may be prepared as an oily or aqueous solid, semi-solid or liquid suppository by a known method.

The contents of the protein possessing cell growth factor activity and proton pump inhibitor in the medicine of the present invention may be chosen as appropriate depending on the situation; for example, the concentration 5 of the protein is normally about 0.0001 to 10% by weight, preferably about 0.001 to 1% by weight, and more preferably about 0.01 to 0.2% by weight. The concentration of the proton pump inhibitor is normally about 0.1 to 90% by weight, preferably about 1 to 50% by weight, and more 10 preferably about 2 to 20% by weight.

The ratio of the protein possessing cell growth factor activity used to the proton pump inhibitor is normally about 0.0001 to 1 times (by weight), preferably about 0.001 to 0.1 times (by weight), of the proton pump inhibitor 15 content, although it varies depending on combinations.

With respect to the medicine of the present invention, a protein possessing fibroblast growth factor activity and a proton pump inhibitor, separately prepared, may be administered to the same subject at the same time, or they 20 may be administered to the same subject at a time interval. The components may have different administration frequencies. The administration frequency of the proton pump inhibitor is preferably one or two per day, more preferably one per day. The administration frequency of 25 the protein possessing fibroblast growth factor activity is preferably 1 to 4 per day, more preferably 3 or 4 per day.

In administering the antiulcer medicine of the present invention, it is preferable that the protein possessing cell growth factor activity be in a state in which acid 30 secretion is suppressed by proton pump inhibitor administration (normally after about 30 - 60 minutes following oral administration of the proton pump inhibitor). If acid secretion is continuously suppressed by daily administration of a proton pump inhibitor, the 35 protein can be administered concomitantly with the proton pump inhibitor.

Although the dose of the antiulcer medicine of the present invention is chosen as appropriate, according to ulcer type and symptoms, the protein possessing cell growth factor activity is administered at 0.01 - 1,000 µg/kg/day, 5 preferably 0.1 - 300 µg/kg/day more preferably 0.1 - 10 µg/kg/day, and the proton pump inhibitor at 0.01 mg/kg/day - 10 mg/kg/day, preferably 0.1 - 3 mg/kg/day, more preferably 0.1 - 1 mg/kg/day. The dosage volume per administration is determined in consideration of such daily 10 dose, dosage form etc.

The medicine of the present invention may include, besides a protein possessing cell growth factor activity and a proton pump inhibitor, an active ingredient such as an antiulcer substance (ex. H₂ blockers).

15

Best Mode for Carrying Out the Invention

Experimental Example 1

Male Jcl:SD rats (weighing about 220 g) at 7 weeks of age were used in the experiment after being fasted for 24 hours. Each rat received oral administration of lansoprazole suspended in vehicle ① containing 1% NaHCO₃ and 0.5% methyl cellulose, or vehicle ① alone. Thirty minutes later, aspirin suspended in 0.5% methyl cellulose (vehicle ②) was orally administered at 200 mg/kg. From 1 hour after aspirin administration, ordinary solid food was given for 2 hours. In experiment 1, CS23 (a human basic fibroblast growth factor mutein) dissolved in vehicle ② containing no NaHCO₃, or the vehicle alone, was orally administered three hours later to subject animals. In experiment 2, CS23 dissolved in vehicle ① containing 1% NaHCO₃, or the vehicle alone, was orally administered three hours later to subject animals. At 24 hours after aspirin administration, animals were sacrificed with gaseous carbon dioxide; the stomach, together with the lower esophagus and duodenum, was excised from each animal. After the esophagus was clipped, 10 ml of 1% formalin was injected

into the stomach via the duodenum, the whole stomach being immersed in 1% formalin. About 15 minutes later, the stomach was incised along the greater curvature, and the contents removed. The length (mm) of each lesion in the 5 gastric body was measured under a dissecting microscope ($\times 10$). For each rat, the length of each lesion was summed, and used as lesion index. The results of experiments 1 and 2 are shown in Tables 1 and 2, respectively.

10 Table 1 Effects of Lansoprazole and CS23 on Gastric Mucosal lesions Induced by Aspirin in Rats (Experiment 1)

Group	Drug (1)	Drug (2)	Number of Animals	Gastric Mucosal lesion Index (mm)	Inhibition (%)
15	1 Veh-①	Veh-②	6	73.5 ± 4.8	
	2 Veh-①	CS23 (0.1)	6	61.5 ± 6.4	16
	3 LPZ (1.0)	Veh-②	6	50.2 ± 8.4	32
	4 LPZ (3.0)	Veh-②	6	34.5 ± 3.1 ^a	53
	5 LPZ (1.0)	CS23 (0.1)	6	36.0 ± 2.2 ^{a b}	51
	6 LPZ (3.0)	CS23 (0.1)	6	13.0 ± 2.1 ^{a b c}	82

25 Drug (1) was orally administered 30 minutes before aspirin administration, and drug (2) 6 hours after aspirin administration.

20 Veh-①: Solution containing 1% NaHCO₃ and 0.5% methyl cellulose

Veh-②: Solution containing 0.5% methyl cellulose

LPZ : Lansoprazole

() : Dose (mg/kg, p.o.)

30 a: p < 0.05 vs group 1; b: p < 0.05 vs group 2; c: p < 0.05 vs group 4

Table 2 Effects of Lansoprazole and CS23 on Gastric Mucosal lesions Induced by Aspirin in Rats (Experiment 2)

5	Group	Drug (1)	Drug (2)	Number of Animals	Gastric Mucosal lesion Index (mm)	Inhibition (%)
10	1	Veh-①	Veh-①	6	76.3 ± 11.6	-
	2	Veh-①	CS23 (0.1)	6	45.5 ± 4.3	40
	3	LPZ (1.0)	Veh-①	6	43.8 ± 5.9	43
	4	LPZ (3.0)	Veh-①	6	28.2 ± 4.2 ^a	63
	5	LPZ (1.0)	CS23 (0.1)	6	29.0 ± 5.5 ^{a b}	62
	6	LPZ (3.0)	CS23 (0.1)	6	15.7 ± 2.2 ^{a b c}	79

15 Drug (1) was orally administered 30 minutes before aspirin administration, and drug (2) 6 hours after aspirin administration.

Veh-①: Solution containing 1% NaHCO₃ and 0.5% methyl cellulose

20 LPZ : Lansoprazole

() : Dose (mg/kg, p.o.)

a: p < 0.01 vs group 1; b: p < 0.05 vs group 2; c: p < 0.05 vs group 4

25 As shown in Tables 1 and 2, lansoprazole (1 and 3 mg/kg) dose-dependently decreased the gastric mucosal lesion index in both experiments, the index for the 3 mg/kg group being significantly lower than that for the control group, which received vehicle alone. CS23 (0.1 mg/kg) showed no action in experiment 1, in which it was 30 administered with vehicle ② not containing 1% NaHCO₃, but caused a 40% reduction in experiment 2, in which it was administered with vehicle ①, containing 1% NaHCO₃. Combined use of lansoprazole and CS23 resulted in marked decrease in lesion index; the lesion indexes for group 6, 35 which received 3 mg/kg lansoprazole and 0.1 mg/kg CS23,

were significantly lower than those for the respective single-drug groups.

These results demonstrate that combined use of the two drugs is useful in the prevention and treatment of ulcers.

5

Preparation Examples

The medicine of the present invention can be, for example, produced with the following formulations.

10 1. Capsule

(1)	lansoprazole	10 mg
(2)	CS23	0.1 mg
(3)	Lactose	90 mg
(4)	Microcrystalline cellulose	70 mg
15	(5) Magnesium stearate	10 mg

Total 180.1 mg per capsule

Components (1), (2), (3) and (4) and a half portion of component (5) are mixed and granulated. To these granules, the remaining portion of component (5) is added, and the 20 whole mixture is packed in a gelatin capsule.

2. Tablet

(1)	lansoprazole	10 mg
(2)	CS23	0.1 mg
25	(3) Lactose	35 mg
(4)	Corn starch	150 mg
(5)	Microcrystalline cellulose	30 mg
(6)	Magnesium stearate	5 mg

Total 230.1 mg per tablet

Components (1), (2), (3) and (4), a two-third portion of component (5) and a half portion of component (6) are mixed and granulated. To these granules, the remaining portions of components (5) and (6) are added, and the whole mixture is tableted by compressive tabletting.

3. Kit

A kit in which each component constitutes a separate preparation is prepared with the capsules A and B.

(a) capsule A

5	(1) lansoprazole	10 mg
	(2) Lactose	90 mg
	(3) Microcrystalline cellulose	70 mg
	(4) Magnesium stearate	10 mg

Total 180 mg per capsule

10 Components (1), (2) and (3) and a half portion of component (4) are mixed and granulated. To these granules, the remaining portion of component (4) is added, and the whole mixture is packed in a gelatin capsule.

15 (b) capsule B

(1) CS23	0.1 mg
(2) Lactose	90 mg
(3) Microcrystalline cellulose	70 mg
(4) Magnesium stearate	10 mg

20 Total 170.1 mg per capsule

Components (1), (2) and (3) and a half portion of component (4) are mixed and granulated. To these granules, the remaining portion of component (4) is added, and the whole mixture is packed in a gelatin capsule.

25

4. kit

A kit in which each component constitutes a separate preparation is prepared with the capsules B and C.

(a) capsule B

30	(1) CS23	0.1 mg
	(2) Lactose	90 mg
	(3) Microcrystalline cellulose	70 mg
	(4) Magnesium stearate	10 mg

Total 170.1 mg per capsule

35 Components (1), (2) and (3) and a half portion of component (4) are mixed and granulated. To these granules,

the remaining portion of component (4) is added, and the whole mixture is packed in a gelatin capsule.

(b) capsule C

5 Nonpareils (Trade-mark), 1650 g, [sugar core prepared by coating sucrose (75 weight parts) with corn starch (25 weight parts) according to a per se known method, 20 to 28 mesh] are brought into the CF (Trade-mark) granulator (CF-360, Freund Industrial Co., Ltd., Japan), and coated, while
10 being sprayed with 1050 ml of a hydroxypropylcellulose solution [2% (w/v)] at 30 ml/min., first with the spraying powder 1 and then with the spraying powder 2, both of which are prepared by mixing the ingredients listed below, at the rate of 60 g/min. at room temperature with a rotor rotating
15 at 200 rpm, dried in vacuo at 40°C for 16 hours, and sieved through round sieves, to give spherical granules (14 to 32 mesh) having a core.

[spraying powder 1]

20	lansoprazole	450 g
	magnesium carbonate	336 g
	granulated sugar	297 g
	corn starch	300 g
	L-HPC	354 g
25	[degree of substitution with hydroxypropaxyl group: 10.0 to 13.0% (w/w), mean particle size : not more than 30 µm]	

[spraying powder 2]

30	granulated sugar	300 g
	corn starch	246 g
	L-HPC (the same one as above)	246 g

The granules obtained as above, 3,800 g, are brought into a fluidized-bed coating vessel (Ohkawara Co., Japan), subjected to enteric coating by spraying the enteric coating film solution described below at the rate of 50

ml/min. under the controlled conditions of inlet air at 65°C and material temperature at 40°C, to give enteric coated spherical granules having a core.

The said granules are mixed with talc and light
5 anhydrous silicic acid, then the mixture is filled into No. 1 hard capsules with a capsule filling machine (Parke-Davis & Co., USA) to give capsules.

[Enteric coating film solution]

10	Endragit L30D-55	2,018 g (solid: 605g)
	talc	182 g
	polyethyleneglycol 6000	60 g
	titanium oxide	60 g
	Tween 80	27 g
15	water	4,230 ml

[composition in one capsule]

	enteric coated granules	368.8 mg
	lansoprazole	30.0 mg
20	magnesium carbonate	22.4 mg
	Nonpareils	110.0 mg
	granulated sugar	59.8 mg
	corn starch	36.4 mg
	L-HPC	40.0 mg
25	hydroxypropylecellulose	1.4 mg
	Eudragit L30D-50	44.6 mg
	talc	13.4 mg
	polyethyleneglycol 6000	4.4 mg
	titanium oxide	4.4 mg
30	tween 80	2.0 mg
	talc	0.6 mg
	light anhydrous silicic acid	0.6 mg
	<u>No. 1 hard capsule</u>	<u>79.0 mg</u>
	Total	449.0 mg

Industrial Applicability

Combined use of a protein, possessing cell growth factor activity, and a proton pump inhibitor for ulcer therapy, according to the present invention, provides rapid 5 and effective therapy, surpassing that of conventional treatments. In addition, doses can be reduced, in comparison with administration of either drug alone.

10

15

20


25

30

35

CLAIMS

1. A medicine which comprises a combination of a protein possessing cell growth factor activity with a proton pump inhibitor.
2. A medicine of claim 1, wherein the protein possessing cell growth factor activity is a protein possessing fibroblast growth factor activity.
3. A medicine of claim 2, wherein the protein possessing fibroblast growth factor activity is a protein possessing basic fibroblast growth factor activity.
4. A medicine of claim 3, wherein the protein possessing basic fibroblast growth factor activity is acid-resistant.
5. A medicine of claim 3, wherein the protein possessing basic fibroblast growth factor activity is a basic fibroblast growth factor (bFGF) mutein showing enhanced acid stability as a result of replacement of at least one bFGF-constituent cysteine with another amino acid.
6. A medicine of claim 5, the bFGF mutein is the recombinant human bFGF mutein CS23 in which cysteine residues at the 70- and 88- positions are replaced by serine residues.
7. A medicine of claim 1, wherein the proton pump inhibitor is a benzimidazole compound.
8. A medicine of claim 7, wherein the benzimidazole compound is a compound of the formula:



wherein ring A may optionally be substituted, R¹, R³ and R⁴ are, the same or different, hydrogen, or an alkyl or alkoxy

group, R² is a hydrocarbon group which may optionally be substituted, and n is 0 or 1, or a salt thereof.

9. A medicine of claim 8, wherein the compound is lansoprazole.

10. A medicine of claim 1, which comprises a combination of the mutoein CS23 with lansoprazole.

11. A medicine of claim 1, which is used to prevent or treat an ulcer.

12. A medicine of claim 11, wherein the ulcer is a peptic ulcer.

13. A medicine of claim 1, which is a kit which comprises a protein possessing cell growth factor activity and a proton pump inhibitor.

14. A medicine of claim 1, which is a pharmaceutical composition which comprises a protein possessing cell growth factor activity and a proton pump inhibitor.

15. A method of producing a pharmaceutical composition which comprises admixing a protein possessing cell growth factor activity with a proton pump inhibitor.

16. Use of a combination of a protein possessing cell growth factor activity with a proton pump inhibitor for the manufacture of a medicine for the prevention or treatment of an ulcerating disease.

17. A method for preventing or treating a ulcerating disease of a mammal, which comprises administering an effective amount of a protein possessing cell growth factor activity in combination with an effective amount of a proton pump inhibitor to the mammal.

18. A method of use of a proton pump inhibitor for enhancing a protein possessing cell growth factor activity.

Apr 4, 1983

TITLE: Mixed drink from fruit- or vegetable juice and liq. protein food - prepd. by previously treating with ion exchange resin to raise pH above IEP of liq. protein

PATENT-ASSIGNEE: EHIME-KEN SEIKA-NOG (EHIMN)

PRIORITY-DATA: 1981JP-0152147 (September 28, 1981)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> <u>JP 58056664 A</u>	April 4, 1983		004	
<input checked="" type="checkbox"/> <u>JP 89015270 B</u>	March 16, 1989		000	

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
JP 58056664A	September 28, 1981	1981JP-0152147	

INT-CL (IPC): A23C 9/15; A23L 2/38

ABSTRACTED-PUB-NO: JP 58056664A

BASIC-ABSTRACT:

Liq. protein food is mixed with fruit juice or vegetable juice previously treated by ion exchange resin to raise pH above IEP of liq. protein food.

Most of fruit juices and vegetable juices have pH below 4.5 and by the treatment with ion exchange resin their pH rises above that of IEP of milk or bean milk, i.e. above 5.0 esp. 5.0-7.0. Either weakly or strongly basic anion exchange resin is used and opt. fruit juice or vegetable juice is previously treated with cation exchange resin for removing alkal(ine earth) metal properly.

Mixed drinks prepd from liq. protein food such as milk and bean milk and fruit juice or vegetable juice, have been known, but they have often suffered from the formation of floc or ppte due to IEP pptn. of protein or electrical cohesion of colloids. New mixed drink which is excellent in taste and flavour and does not suffer from formation of floc or ppte can be prepd without stabiliser, etc.